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ABSTRACT 
Type 2 diabetes is an increasingly prevalent disease posing great burdens to 
healthcare, in which obesity and adipose tissue (AT) dysfunction are central components 
of disease progression. Impairment of insulin signaling and inflammation in AT can 
trigger insulin resistance but an improved understanding of metabolic dysfunction during 
disease progression is necessary to identify novel targets for therapeutics. G-protein 
pathway suppressor 2 (GPS2) plays an important role as a mediator of lipid metabolism 
and inflammatory responses, both processes regulating insulin resistance, but GPS2 exact 
function in AT remains unknown. These data suggest GPS2 in AT plays an important 
role in systemic regulation of metabolic homeostasis and dissecting GPS2 function in AT 
is therefore critical for understanding how metabolic and inflammatory pathways are 
inter-regulated during the development of insulin resistance. These studies describe the 
characterization of the adipocyte-specific GPS2 knockout (GPS2-AKO) mouse model. A 
novel layer of regulation in the insulin signaling cascade was identified, based on 
ubiquitin conjugating enzyme E2N (Ubc13)-mediated K63 ubiquitination of protein 
kinase B (AKT). GPS2 was found to be a negative regulator of this pathway through 
inhibition of Ubc13. Loss of GPS2 promoted AKT hyperubiquitination and activation 
		 ix 
and enhanced insulin signaling in adipocytes, a mechanism conserved in other cell types. 
Phenotypic characterization of GPS2-AKO mice showed they developed increased body 
weight and AT mass when fed chow diet. The white AT (WAT) was characterized by 
adipocyte hypertrophy, a result of impaired lipolysis and increased lipogenesis. Similarly, 
brown AT (BAT) acquired a WAT phenotype caused by increased lipid accumulation 
from compromised lipolysis and defective mitochondrial biogenesis. Despite significant 
increases in adiposity, GPS2-AKO mice had improved systemic insulin sensitivity due to 
enhanced insulin signaling and lipid storage capacity. Observations indicated GPS2-AKO 
mice on high fat diet (HFD) became excessively obese and inflamed, yet displayed 
reduced peripheral tissue lipid deposition and remained metabolically healthy. This work 
describes how GPS2 modulates systemic metabolism by regulating insulin signaling, 
lipid storage capacity, mitochondrial biogenesis and inflammation. Dissecting GPS2 
function in AT provides insight into points of regulatory convergence among pathways 
connecting AT to systemic metabolic regulation, helping to uncover innovative targets 
for the treatment of metabolic disorders. 
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CHAPTER ONE - INTRODUCTION 
Metabolic Syndrome and Type 2 Diabetes 
Hallmarks of disease progression and insulin resistance 
 The metabolic syndrome (MetS) is broadly defined as a cluster of pathological 
conditions including hypertension, glucose intolerance, dyslipidemia, and excessive 
central body fat that when all occurring in combination increase an individual’s risk of 
heart disease, stroke, and diabetes mellitus1,2. The prevalence of MetS is increasing 
worldwide and becoming a serious health concern, especially in aging populations. 
Studies conducted to evaluate the occurrence of this syndrome determined that the overall 
prevalence of MetS in the United Studies in 2011-2012 was roughly 35% and close to 
50% in adults over the age of 603. Although various genetic components associated with 
MetS have been suggested by genome-wide association studies, typical risk factors 
mainly include sedimentary lifestyle, increasing age, excessive caloric intake and obesity 
and non-alcoholic fatty liver (NAFL) disease1,2. The presence of MetS can lead to various 
complications and is highly predictive for prognoses of cardiovascular disease (CVD) 
and Type 2 diabetes mellitus (T2D) 1,2. T2D, also known as adult onset diabetes, is a 
chronic condition in which the body cannot properly metabolize and store glucose, 
resulting in hyperglycemia1,2,4-6. This disease has become an epidemic in which there are 
approximately 150 million people worldwide with T2D and this figure is estimated to 
double by the year 20206. In this condition, metabolic tissues of the body are 
unresponsive to the effects of insulin and b cells within the pancreas are no longer able to 
produce the appropriate amount of insulin necessary to maintain glucose homeostasis1,2,4-
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6. Insulin resistance is a hallmark and key component of the pathophysiology of these 
diseases.  
Insulin resistance (IR) is clinically defined as the inability of a fixed amount of 
endogenous/exogenous insulin to increase glucose uptake and utilization4-6. IR can 
manifest itself in many ways in MetS and T2D. Impaired insulin signaling in muscle, for 
example, causes extensive systemic insulin resistance as muscle is a central organ in 
regulating insulin-stimulated glucose disposal. Additionally, insulin resistance in the liver 
leads to increased hepatic glucose output that contributes to dyslipidemia because proper 
insulin action in the liver is important to suppress hepatic gluconeogenesis and 
glycogenolysis. Dysfunctional insulin signaling in adipose tissue also results in impaired 
fat tissue expansion, lipid spillover, and low-grade chronic inflammation, which can in 
turn promote IR in other tissues. The brain also plays a role in disease progression 
because IR in this tissue contributes to fasting hyperglycemia and compromised appetite 
regulation (Figure 1.1)4-6. The most notable risk factor for T2D and insulin resistance is 
obesity, specifically visceral adiposity4. This disease can be managed; however, various 
complications can manifest that require constant clinical care resulting in enormous 
burdens for health care systems worldwide. This has triggered an immediate need for 
increased drug discovery and novel therapeutics for insulin resistance and T2D.  
Adipose tissue and its role in metabolism 
 Although traditionally defined as a passive organ responsible for nutrient storage, 
insulation, and mechanical support, adipose tissue (AT) is now appreciated as an active 
endocrine organ highly involved in organismal metabolism7-9. It is responsible for 
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coordinating endocrine and paracrine metabolic cues from various tissues and is a 
professional secretory organ, releasing various adipokines and cytokines to regulate 
pathways involved in maintaining homeostasis during fasting and feeding. For example, 
AT can release adiponectin, an insulin sensitizing hormone, and leptin, a satiety hormone, 
as well as others to manage systemic nutritional status, food intake and energy 
expenditure7-10. As a nutrient storage depot, AT is a vastly dynamic tissue with immense 
metabolic flexibility for expansion and contraction to influence systemic lipid 
homeostasis. Specifically, adipose tissue controls the surplus storage of energy in the 
form of neutral triglycerides (TG) via the process of de novo lipogenesis (DNL). When 
energy expenditure requirements increase or under low nutrient conditions, AT can 
breakdown TGs into free fatty acids (FFAs) and glycerol via lipolysis which are released 
into circulation to provide energy for other tissues7-9.  
Individual AT depots are complex and heterogeneous organs that are comprised 
of many cell types to aid in functional competency of the depot as a whole. These cells 
include adipocytes, adipocyte progenitors, fibroblasts and various vascular cells, and 
macrophages and numerous other immune cells11,12. Many of these cell types allow AT 
depots to properly respond to nutritional cues. This occurs through various cellular and 
structural remodeling processes that include tissue expansion through hypertrophy and 
hyperplasia, recruitment of immune cells, and remodeling of the vasculature and ECM. 
These processes allow adequate oxygenation and mobilization of nutrients during 
remodeling to allow for lipid storage or the release of energy stores when necessary.  
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There are different subclasses of adipose tissue which are broadly divided into 
white and brown adipose tissues. The white adipose tissue (WAT) consists of large, 
unilocular lipid droplet filled adipocytes whose primary responsibility is nutrient 
storage13,14. The brown adipose tissue (BAT), on the other hand, consists of multilocular 
lipid droplets, mitochondria-rich and UCP1 expressing adipocytes, whose primary 
function is involved in regulating energy expenditure and thermogenesis13,14. 
Additionally, the WAT depots can be subclassified based on the anatomical location of 
these depots. Two of the most notable and studied WAT depots are the visceral and 
subcutaneous depots, which differ in cellular, molecular and structural features involved 
in remodeling, adipogenic potential, vascularization, and immune cell populations. 
Interestingly, different adipose tissue depots correlate differently with risk factor for 
metabolic dysfunction. Visceral adipose tissue correlates with a higher incidence of Type 
2 diabetes whereas subcutaneous adipose tissue does not assume this same 
correlation12,15. While AT is required to maintain proper metabolism, an excessive 
accumulation of WAT in humans is the most predominant factor associated with insulin 
resistance and low-grade chronic inflammation resulting in whole body metabolic 
dysfunction. Although alternations in WAT mass occur in healthy individuals, it becomes 
clinically relevant when excessive WAT mass associates with various health problems. 
Obesity as a major risk factor for insulin resistance and T2D  
 Obesity, which has become a pandemic, has been established as a profound factor 
contributing to insulin resistance and T2D. Obese AT releases increased amounts of 
FFAs, glycerol, adipokines, pro-inflammatory cytokines and other factors involved in the  
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Figure 1.1 –Mechanisms of obesity-induced insulin resistance. 
Obesity drives defects in multiple tissues to induce systemic insulin resistance. Insulin 
resistant tissues propogate tissue defects resulting in metabolic dysfunction and T2D. 
This figure was adapted from: Oh da, Y. & Olefsky, J. M. G protein-coupled receptors as 
targets for anti-diabetic therapeutics. Nat Rev Drug Discov 15, 161-172, 
doi:10.1038/nrd.2015.4 (2016).16 
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development of insulin resistance (Figure 1.1). Adipocytes have an immense capacity to 
synthesize and store TGs during feeding and hydrolyze and release TGs as FFAs and 
glycerol during fasting. During early stages of obesity, adipocytes are still able to 
maintain normal cycles of TG storage and lipolysis, albeit expressing higher levels of 
various enzymes involved in TG synthesis to manage the increased lipid load. However, 
as adiposity increases, the ability of adipocytes to regulate lipolysis, lipogenesis and 
insulin-stimulated glucose transport is greatly impaired7,17-19. When adipocytes become 
too large they become dysfunctional and cannot properly store FFAs as neutral lipids. 
These fatty acids can be inappropriately stored in peripheral tissues as well as in 
circulation to drive insulin resistance and dysfunction of other tissues, most commonly 
the liver and skeletal muscle7,17-19. Toxic lipid species can also increase and exacerbate 
both AT and systemic metabolic dysfunction. Under obese conditions adipocytes are 
unable to appropriately secrete adipokines and cytokines and respond to circulating 
metabolic signals. These dysfunctions elicit an inflammatory response to aid in the 
buffering of lipids and the remodeling of the tissue7,17-19. If these inflammatory pathways 
in the AT are not under proper control they are thought to contribute to the progression of 
insulin resistance and T2D as well. As AT insulin signaling dysfunction is a principal 
mediator of many of these metabolic defects, this will be described in a subsequent 
introductory chapter.  
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Insulin signaling pathway in adipose tissue 
Overview and pathway members 
Insulin is an important anabolic hormone produced by b cells in the pancreas. It 
regulates whole body metabolism by modulating the uptake of circulating glucose, fatty 
acids and amino acids in target tissues20-24. The insulin signaling cascade in adipocytes 
has been studied in many facets. Downstream mediators of this pathway have been 
shown to regulate glucose storage and uptake, protein synthesis and lipid synthesis. 
Insulin-mediated signal transduction and transcription is also responsible for regulation of 
pathways involved in growth and proliferation, gluconeogenesis and glycogen synthesis, 
lipolysis, cholesterol synthesis, apoptosis and autophagy20-24.  
Insulin exerts its actions by stimulating a complex signal transduction cascade 
activated upon binding to the insulin receptor (Figure 1.2). The insulin receptor belongs 
to a subfamily of receptor tyrosine kinases and is comprised of a tetrameric protein 
complex with two extracellular a and two transmembrane b subunits20-24. These subunits 
function as allosteric enzymes where the a subunit inhibits the tyrosine kinase activity of 
the b subunit when ligand is not present. Upon insulin binding, the a subunit undergoes 
conformational changes to derepress the kinase activity of the b subunit. This 
immediately leads to phosphorylation of the b subunit, additional b subunit 
conformational changes and increased kinase activity of the receptor20-24. The insulin 
receptor then phosphorylates a number of intracellular substrates to initiate a complex 
network of signaling cascades. Nine direct insulin receptor substrates have been 
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identified thus far: 4 IRS proteins, Gab-1, p60, Cbl, APS, and Shc isoforms20-24. The 
phosphorylated tyrosine residues on these proteins act as docking sites for SH2 domain 
containing target proteins to further mediate downstream signaling kinase cascades. The 
main intracellular pathways activated by insulin include the PI3K/AKT pathway, the 
Ras/MAPK/ERK pathway, and the CAP/Cbl pathway20-24. The PI3K/AKT pathway is 
responsible and necessary for many of the effects of insulin and is the primary insulin-
stimulated pathway we have focused on in this thesis.  
Keeping the insulin signaling cascade under tight regulation is reflected by the 
presence of many negative regulators. Inhibition of insulin receptor signaling can be 
accomplished by inhibitory serine phosphorylation events leading to interaction between 
the IRS proteins with 14-3-3 to turn off downstream signaling. Inhibition of this pathway 
also occurs through protein tyrosine phosphatases (PTPases) which catalyze the swift 
dephosphorylation of the receptor and its various substrates to similarly shut off insulin-
mediated signals20-24. Significant progress has been made to understand the molecular 
details of the insulin signaling pathway. 
The role and regulation of AKT in the insulin signaling pathway 
Protein kinase B, AKT/PKB, is a serine/threonine kinase that has been identified 
as a critical component of multiple cellular pathways regulating cell growth, survival, 
proliferation, and metabolism. Particularly, regulation of insulin signaling in AT relies on 
the activation of AKT20-24. Three isoforms of AKT have been identified, each with 
distinct functions. AKT2 is the predominant isoform involved in metabolism and 
regulation of insulin action on glucose transport, whereas AKT1 has been linked to cell  
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Figure 1.2 – The canonical insulin signaling pathway. 
Insulin action results in the activation of multiple downstream signaling cascades to 
affect a variety of cellular processes. This figure was adapted from Siddle, K. Signalling 
by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47, R1-
10, doi:10.1530/JME-11-0022 (2011).25 
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growth, survival and apoptosis and AKT3 has a suggested function in brain 
development20,22,25-27.  
Although AKT isoforms have been shown to play different roles, all isoforms 
have a conserved structure that consists of an N terminal PH domain, a central kinase 
domain, and a C terminal regulatory domain comprised of a hydrophobic motif. The PH  
domain of AKT plays a critical role in recognition by upstream kinases as well as for the 
recruitment of AKT to the plasma membrane. This domain binds to membrane lipid 
products, such as the second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3) 
produced upon activation of the phosphatidylinositol 3-kinase (PI3K) by the insulin 
receptor24-26. The kinase domain of AKT is similar to other ACG kinases, containing a 
conserved threonine residue that undergoes phosphorylation to activate the critical 
enzymatic activity of AKT24-26. The C terminal hydrophobic motif also contains a 
conserved site of phosphorylation to allow for full activation of AKT24-26.  
Following AKT translocation to the membrane, the kinase is phosphorylated on 
two specific sites, threonine 308 in the catalytic domain by PDK1 and serine 473 in the C 
terminal hydrophobic domain by mTORC2. The phosphorylation events stabilize AKT in 
an active conformation, leading to the activation of an intricate network of downstream 
signaling cascades20,22,25-27. Some key examples include AKT phosphorylation of AS160 
involved in GLUT4 translocation, AKT phosphorylation of GSK3b to modulate glycogen 
and fatty acid synthesis, as well as AKT phosphorylation of kinases involved with 
mTORC1 to regulate growth and proliferation20,22,25-27. Negative regulation of AKT can 
be achieved by the actions of PTEN which is able to negatively regulate intracellular 
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levels of PIP3 to inhibit AKT action as well as via negative regulation of upstream 
mediators in the insulin signaling cascade20,22,25-27.  
Insulin signaling in the development of insulin resistance 
Defects in the insulin signaling cascade have been associated with the 
development of insulin resistance in adipose tissue, muscle, and liver. Studies in both 
mice and humans have shown that both genetics and environment have been found 
responsible for these defects. Various mutations in the insulin receptor, IRS proteins, 
PI3K activity and AKT have been identified and targeted deletion of these components 
have shown their ability to drive insulin resistant phenotypes20,22,25-27. Patients with rare 
genetic defects in insulin receptor expression, binding, phosphorylation state and kinase 
actvity have shown that these alterations can account for insulin resistance28. Specific 
deletion of IRS proteins have revealed their importance in the development of insulin 
resistance as well. IRS-1 knockout mice show a phenotype of growth retardation, insulin 
resistance in peripheral tissues and impaired glucose tolerance whereas IRS-2 knockout 
mice present a phenotype of insulin resistance in peripheral tissues and modest defective 
growth in some tissues, mainly various regions of the brain29-32. Mice with systemic 
knockout of AKT2 were also found to develop insulin resistance in muscle and liver 33. 
Elevated FFAs have been found associated with reduced insulin-stimulated IRS-1 
phosphorylation as well as reduced PI3K activity34. These and additional models have 
highlighted the importance of players in the insulin signaling cascade in the development 
of T2D.  
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Lipotoxicity induced by insulin resistance can lead to several impairments in the 
insulin signaling cascade as well. Impaired glucose uptake as a result of impaired insulin 
signaling acts as a feed forward mechanism to propagate the insulin resistant phenotype. 
Unrestricted circulation of FFAs can mediate many inhibitory effects on the insulin 
signaling pathway as well. 20,22,25-27It has been shown that fatty acids can also act as 
ligands to activate TLR signaling pathways to induce pro-inflammatory signals that 
impair insulin action through activation of JNK resulting in IRS-1 inactivating 
phosphorylation events. Sphingolipid ceramides have also been shown to inhibit insulin-
stimulated AKT activation via activation of TNFa20,22,25-27. Inflammatory effects on 
insulin signaling and insulin resistance will be discussed further in a subsequent section. 
Overall, tight regulation of insulin signaling is extremely important to maintain metabolic 
homeostasis and interrupted insulin-mediated signaling cascades result in insulin 
resistance and T2D.  
AKT regulation by ubiquitination in signaling pathways 
 It is well appreciated that AKT activation requires its translocation to the plasma 
membrane and binding to membrane lipids via the PH domain. This was eloquently 
illustrated by showing that adding a myristylation residue to AKT could sufficiently drive 
its translocation to the membrane and induce its activation, regardless if upstream insulin 
signaling was not active35. Despite these results, the exact cues that target and drive AKT 
movement to the membrane or other factors involved in the regulation of this 
translocation are less elucidated.  
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Recent work has revealed that non-proteolytic ubiquitination of AKT might be a 
contributing factor for the kinase recruitment to the plasma membrane, phosphorylation, 
and thus activation36-39. Specifically, it was shown that upon IGF and IL1b stimulation, 
the E3 ubiquitin ligase, Traf6, promoted the ubiquitination of AKT40. TRAF6-mediated 
K63 ubiquitination was required for AKT translocation to the plasma membrane, 
phosphorylation and activation upon growth factor stimulation (Figure 1.3). Lysine 
residues 8 and 14 within the PH domain of AKT were identified as ubiquitination sites 
necessary for AKT ubiquitination and activation40. A similar mechanism was later 
observed in response to EGF stimulation in which another E3 ligase, Skp2, was 
responsible for the K63 ubiquitination of AKT41. Again, the ubiquitination of AKT by 
Skp2 was required for AKT recruitment to the plasma membrane and in turn its 
phosphorylation and activation41. In addition, deubiquitination of AKT via the actions of 
the deubiquitinase, CYLD, appeared to counteract AKT activation. CYLD deficiency led 
to hyperactive AKT membrane recruitment and activation in response to growth factor 
stimulation42.  
In humans AKT ubiquitination has been predominantly studied in the context of 
activating cancer mutations, such as that of oncogenic AKT1 mutant E17K, which drives 
increased ubiquitination and hyperactivation of AKT and downstream growth promoting 
pathways43. However, there is one patient case study in which it was observed that the 
same mutation in AKT2 led to enhanced AKT activation, insulin signaling, 
hypoglycemia and hypoinsulinemia44,45. Although no connections with non-proteolytic 
ubiquitination of AKT and insulin siganling have been made, these data suggest that  
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Figure 1.3 –Model of AKT ubiquitination. 
Upon certain growth factor stimulation, AKT undergoes K63 ubiquitination, which 
results in membrane translocation and subsequent phosphorylation and activation. This 
figure was adapted from: Yang, W. L., Wu, C. Y., Wu, J. & Lin, H. K. Regulation of Akt 
signaling activation by ubiquitination. Cell Cycle 9, 487-497 (2010).36 
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aberrant AKT ubiquitination could be similarily affecting insulin signaling and promoting 
metabolic dysfunction. 
Obesity-associated inflammation 
Overview 
Over the past couple of decades, a great deal of epidemiological evidence has 
revealed a strong correlation between inflammation and obesity-induced insulin 
resistance46-56. Obesity-associated inflammation is now a widely recognized critical factor 
in the development of insulin resistance and T2D46-56. Although many studies have 
revealed a clear association between chronic, low-grade inflammation and activation of 
pro-inflammatory signaling cascades with decreased insulin sensitivity, the exact 
physiological events leading to the initiation of inflammatory signaling and obesity is not 
well understood. Interestingly, local inflammation in the adipose tissue has been shown to 
positively affect metabolic flexibility57. In agreement, therapeutic interventions using 
anti-inflammatory drugs have proven largely unsuccessful in treating metabolic diseases 
in clinical trials58. Thus, it appears inflammatory pathway contributions to inducing 
insulin resistance and vice versa are more complex than initially envisioned. 
In the search for mechanisms responsible for the pathogenesis of obesity 
associated insulin resistance, a close relationship between excessive nutrient stress and 
aberrations in mediators of immunity and inflammation have been uncovered. This led to 
the development of the concept of “metainflammation” describing the low-grade chronic 
inflammatory response to obesity46-56. In general terms, inflammation is a coordinated 
response to harmful stimuli to remove pathogens and restore homeostasis. Adipose tissue 
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inflammation involves many components of classically activated inflammatory 
responses, such as increased circulation of inflammatory cytokines, recruitment and 
activation of immune cells into the impaired tissue, and production of reparative 
responses46-56. However, AT inflammation/metainflammation in response to obesity is 
unique compared with canonical inflammation, such as infection or autoimmune diseases.  
Obesity induces both a persistent low-grade activation of immune cells that over 
time can negatively affect metabolic homeostasis as well as acute attacks of nutrition-
related immune cell activation induced by excessive nutrient availability and associated 
stress signals46-56. Obesity-induced chronic inflammation leads to increased pro-
inflammatory changes in not just AT but also multiple organs including liver, muscle, 
pancreas and the brain46-56. This multi-organ inflammation associated with obesity 
presents a unique disease state and creates a difficult challenge to tease out direct 
mechanisms in the involvement of adipose tissue dysfunction and inflammation in the 
onset of insulin resistance.  
Obesity driven AT inflammation  
 A long standing debate has been how obesity and inflammation can 
synergistically and separately drive insulin resistance. The discovery that obesity directly 
induces polarization of AT macrophages suggested that obesity can itself drive pro-
inflammatory responses in the tissue leading to metabolic dysregulation59,60. Adipose 
tissue insulin resistance and dysfunctional lipid storage are important events that can 
cause proinflammatory responses (Figure 1.4). A reduced ability for AT to store 
excessive lipids, resulting in lipid spillover has been proposed as a potential factor46-56. 
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Lipid spillover can induce macrophage infiltration into the AT. Direct and paracrine 
signals from pro-inflammatory macrophages can in turn impair insulin signaling and 
adipogenesis in adipose tissue46-56. Additionally, FFAs from improper lipid storage can 
activate inflammatory pathways and serve as ligands for TLR2/4 to induce JNK and 
NFkB to stimulate pro-inflammatory gene transcription and impair insulin signaling46-56.  
WAT also acts as an endocrine organ and releases cytokines, including IL6, IL1b, 
TNFa, and MCP1. These stress signals are typically activated when excessive 
hypertrophy results in cell death. Increased activation of NFkB transcriptional programs  
results in increased production of proinflammatory cytokines such as TNFa, IL6, IL1b, 
and MCP1 to further activate pro-inflammatory gene transcription in a feed forward 
mechanism46-56.These cytokines also help to recruit immune cells into AT and contribute 
to pro-inflammatory signaling. Immune cells can then polarize to create a pro-
inflammatory environment in the adipose tissue and feed back to the adipocyte to cause 
decreased IRS-1 and AKT phosphorylation as well as GLUT4 translocation. This cascade 
is thought to continuously signal to drive chronic adipose tissue inflammation46-56. 
Obesity can furthermore cause increased adipocyte cell death which contributes to 
immune cell infiltration into the tissue to clean up the cellular debris46-56. Due to 
increased adipocyte hypertrophy and lack of sufficient blood supply to reach the over-
expanded tissue, hypoxia has also been implicated to propagate inflammation associated 
with obesity46-56. Hypoxia has been shown to activate HIF1a which can activate NFkB 
signaling46-56. ER stress has been implicated in causing inflammation in obesity as well. It 
has been shown that overnutrition can cause activation of the unfolded protein response  
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Figure 1.4 –Model of AT inflammation. 
Obesity and dysregulated inflammatory signaling coordinately result in AT dysfunction. 
This causes macrophage infiltration, polarization of immune cells to pro-inflammatory 
phneotypes and increased production of pro-inflammatory signals in AT. This figure is 
adapted from:	 Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking 
the immune system and metabolism in disease. Nat Med 18, 363-374, 
doi:10.1038/nm.2627 (2012).61  
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and ER stress, which can activate JNK and cause defective insulin signaling46-56. Lipid 
intermediates such as DAGs, ceramides and sphingolipids can also induce adipocyte cell 
stress and pro-inflammatory signaling cascades46-56. Lastly, oxidative stress and 
mitochondrial dysfunction have been suggested as cell-intrinsic mechanisms to drive 
metabolic tissue inflammation.  
AT inflammation driving insulin resistance  
 As much as AT dysfunction can drive pro-inflammatory signaling activation, 
increased inflammation can also drive adipose tissue and systemic metabolic dysfunction, 
creating a pathophysiologic feedforward loop to drive insulin resistance (Figure 1.4). 
Many theories have developed as to how inflammation contributes to obesity-induced 
insulin resistance. In seminal work by Hotamisligil and Spiegelman, TNFa was shown to 
inhibit insulin signaling in adipocytes and contribute to obesity-induced insulin 
resistance, which was the first evidence that adipose tissue inflammation was pertinent in 
metabolic dysfunction62-65. TNFa has been found to be upregulated in obese insulin 
resistant patients and TNFa stimulation leads to the activation of the stress kinase, JNK, 
which was then found to directly serine phosphorylate IRS1 to inhibit its ability to 
mediate the insulin signaling pathway. Once activated, JNK is also able to translocate to 
the nucleus and activate transcription factors such as C-Jun and ATF2 to induce pro-
inflammatory gene expression46-56. Since these initial observations, many other 
mechanisms of inflammation have been implicated in the development of insulin 
resistance.  
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Multiple inflammatory signals contribute to adipose tissue dysfunction, including 
increases in circulating cytokines, decreases in protective, insulin sensitizing factors, such 
as adiponectin, and communication between inflammatory cells and adipocytes. Obesity 
has been shown to activate stress signals such as increased FFAs, ROS, hyperglycemia 
and increased cytokine production which can activate TNFa, TLR and NLR, NOD like 
receptor, signaling cascades46-56. These cellular stress signaling pathways typically 
converge on the activation of JNK as previously mentioned, as well as IKK and NFkB. 
Briefly, the IKK complex is recruited and activated which then phosphorylates IkBa, the 
inhibitory protein that normally binds to NFkB and inhibits its translocation, causing 
IkBa degradation and allows NFkB to enter the nucleus and mediate transcription of an 
inflammatory gene program and production of pro-inflammatory cytokines, such as 
MCP1, TNFa, IL6, IL1b and more. This can lead to increased ROS production and 
hypoxia in the adipose tissue. Overall, cytokine production and increased lipid species 
leads to hyperactivation of inflammatory pathways exacerbating their negative impact on 
adipocytes. Inflammatory cytokines produced by dysfunctional adipose tissue can also 
increase SOC3 expression which can also interfere with insulin receptor activity, 
similarly how JNK can impair IRS activity46-56. Overall, adipose tissue inflammation can 
impair glucose transport, adipocyte function and insulin sensitivity, yet more in depth 
understanding of how inflammation directly inhibits these processes is necessary.  
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Macrophage infiltration into adipose tissue and involvement in remodeling 
 Immune system cells involved in these inflammatory responses include 
macrophages, dendritic cells, mast cells, neutrophils, T cells, B cells, and NK cells. 
Particularly, obesity has been shown to lead to increased infiltration of macrophages into 
the adipose tissue47-50. Macrophages are derived from monocytes and act phagocytically 
to engulf and digest unwanted substances such as cellular debris or foreign species. Other 
immune cells are also found in adipose tissue depots however macrophages are the most 
dominant, representative of approximately 40-60% of cells in the adipose tissue, and 
functionally central47-50. AT macrophages can have different phenotypes, described as 
M1 classically activated or M2 alternatively activated. M2 macrophages are uniformly 
dispersed throughout the adipose tissue, specifically express ARG1, CD206 and CD301, 
and have been shown to assist remodeling of the tissue. These macrophages are less pro-
inflammatory than M1 macrophages and produce IL10, an anti-inflammatory cytokine 
that helps to maintain and potentiate insulin signaling in adipocytes47-50. 
M1 classically activated macrophages have a pro-inflammatory phenotype, 
expressing NOS2, TNFa, CD11C, and are typically observed in a setting of obesity47-50. 
Often, these macrophages are found in crown-like structures around dying adipocytes, 
where they are able to phagocytose lipids released from the necrotic cells to help reduce 
lipotoxic species release into circulation. Fatty acids have also been shown to promote 
M1 macrophage recruitment into adipose tissue. M1 macrophages secrete pro-
inflammatory cytokines that can exacerbate adipose tissue inflammation47-50,66. Although 
these two phenotypes for macrophages have been described as very distinct populations, 
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adipose tissue macrophages exhibit plasticity and can encompass a wide spectrum of 
activation phenotypes that cannot solely be defined as M1 or M2.  
Macrophages are mainly recruited into adipose tissue depots through the 
production of MCP1 from adipocytes which is the main chemoattractant for macrophage 
infiltration into tissues67. Interesting, macrophage recruitment has been shown more 
recently to have a positive function in the adipose tissue. In an interesting study, 
macrophage infiltration into adipose tissue has been shown to be required for healthy 
expansion of the adipose tissue31. In general, resident macrophages help to remodel the 
adipose tissue to allow for expansion and response to metabolic cues57,68. Further 
expansion of these studies can help clarify the role for polarized macrophages in obesity 
and how they may be targeted to treat metabolic syndromes.  
Ubiquitination as a mechanism of post translational modifications in signaling 
pathways 
Overall mechanism of ubiquitination 
 Ubiquitination, also known as ubiquitylation, is a reversible posttranslational 
modification involved in nearly all cellular processes. Ubiquitin is a small, 76 amino acid 
and lysine rich, regulatory protein. It is universally expressed in eukaryotes and beyond 
its essential function for protein degradation processes, it is also involved in a myriad of 
other biological events, resembling other posttranslational modifications such as 
phosphorylation. Ubiquitination is the enzymatic process by which one single ubiquitin 
protein or a chain of ubiquitin molecules is added to a substrate protein. This 
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modification often marks the target protein for proteasomal degradation, however non-
degradative ubiquitin marks also exist69-75.  
The process of ubiquitination is regulated by three main classes of enzymes. 
These include ubiquitin-activating enzymes (E1), ubiquitin conjugating enzymes (E2) 
and ubiquitin ligases (E3). The diversity of these enzymes allows for profound specificity 
of substrate recognition. There are two E1s identified, approximately 50 E2 enzymes, and 
hundreds of E3 enzymes which control the three stages of ubiquitination known as 
activation, conjugation, and ligation69-75. The first step involves the ATP-dependent 
activation of the ubiquitin molecule by the E1 enzyme which forms a thioester bond with 
ubiquitin. Subsequently, the ubiquitin conjugating enzyme (E2) is necessary to transfer 
the ubiquitin from the E1 to the active cysteine site of the E2 via an additional thioester 
bond. The E2 enzyme has a specific structure that allows it to bind the ubiquitin and E1 at  
the same time to allow this step to occur. Finally, the ubiquitin ligase (E3) is required to 
recognize and bind the target substrate and covalently attach the ubiquitin molecule to it. 
Two distinct E3 families of enzymes exist based on the presence of two domains, known 
as the homologous to E6-AP carboxyl terminus (HECT) domain or really interesting new 
gene (RING) domain. For HECT domain E3s, ubiquitin is transferred to the HECT 
domain of the enzyme followed by its transfer to the substrate. Evidence from studies on 
RING domain E3s suggest that ubiquitin can be transferred directly from the E2 to the  
substrate. In both cases, the reaction generates an isopeptide bond between ubiquitin and 
a lysine residue on the substrate protein69-75. If the enzymatic process is repeated multiple 
times, several ubiquitin molecules can be added to form a ubiquitin chain in which each  
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Figure 1.5 –The ubiquitination pathway. 
Ubiquitination is a multiple step enzymatic process that involves three classes of enzymes 
to ultimately add ubiquitin to a target substrate. This figure was adapted from: Weissman, 
A. M. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2, 169-178, 
doi:10.1038/35056563 (2001).71 
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ubiquitin is conjugated to a lysine residue on the previous one (Figure 1.5). Removal of 
ubiquitin chains, or deubiquitination, is mediated by deubiquitinating enzymes, DUBs, 
which act as thiol proteases to specifically cleave this posttranslational modification76.  
Differential ubiquitin chain formations 
 The way in which ubiquitin molecules are linked to each other to form chains and 
how they are linked to protein subtrates provides extreme flexibility to this 
posttranslational modification strategy. Because ubiquitin itself has seven conserved 
lysine residues, which are all potential sites of isopeptide linkage, the choice of lysine 
position to build a multi-ubiquitin chain can result in a multitude of protein substrate 
fates69-75.  
The most notable and studied type of chain has been K48 ubiquitin chains, which 
are involved in tagging proteins for proteosomal degradation. These specific chains are 
recognized by the 26S subunit of the proteasome. K11 chains have also been shown to be 
involved in targeting substrate proteins for proteasomal degradation, specifically in the 
context of cell cycle regulation during mitosis. Monoubiquitination or the addition of 
multi monoubiquitin marks have been implicated in mediating protein interactions, 
localization, and protein activity. K63 ubiquitination has been shown to be involved in 
activation of kinase signaling cascades in the context of inflammatory pathways, DNA 
repair, general trafficking, endocytosis, and protein-protein interactions. K6, K27, K29 
and K33 linked chains are also under investigation and have been implicated in protein 
degradation and DNA repair. Additionally, ubiquitin chains of mixed topology are also 
being identified and their functions are under intense investigation69-75. In conclusion, 
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different types of ubiquitin chains can be formed to function for specific applications and 
this ubiquitin code is still being unraveled. 
Role of K63 ubiquitination in various signal transduction pathways 
 K63 ubiquitination is a non-proteolytic posttranslational mark involved in the 
regulation of various cellular processes and signaling pathways37,69-71,77,78. Currently, 
Ubc13 is the only identified E2 ubiquitin conjugating enzyme responsible for K63 
ubiquitin chain formation. It works in concert with the cofactor, Uev1A, to promote full 
activation to catalyze K63 chains. Uev1A has a similar structure to Ubc13, however lacks 
the catalytic domain critical for E2 function. Ubc13/Uev1A cooperate with various E3 
ubiquitin ligases to confer substrate specificity and differential pathway regulation37,69-
71,77,78. 
This posttranslational modification has an important function in the nucleus. It has 
been shown to be essential in mediating the recruitment of DNA damage repair 
machinery. Specifically, nuclear Ubc13 has been shown to act with the E3 ubiquitin 
ligase, RNF8, to recruit repair factors involved in homologous recombination to properly 
regulate DNA repair upon double strand breaks. Additionally, Ubc13 works with other 
nuclear E3s to regulate DNA replication stress37,69-71,77,78. More recently, Ubc13-mediated 
K63 ubiquitination has been found to recruit chromatin remodeling machinery as well. 
Our lab has demonstrated the functions of Ubc13/RNF8 to help remodel chromatin 
landscapes necessary to allow PPARg binding and activation of a subset of PPARg target 
genes79. K63 ubiquitination clearly plays an important nuclear role which should be 
studied in further detail to elucidate other mechanisms.  
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K63 ubiquitination is also an important posttranslational modification used to 
mediate inflammation and immune response pathways37,77,78. Ubc13-mediated K63 
ubiquitin chains have been found to be involved in multiple stages downstream TNFa, 
TLR ligand, and IL1b stimulation to activate NFkB and MAPK signaling. For example, 
Ubc13 has been shown to interact with the RING domain of TRAF2 in the TNFa 
receptor signaling pathway to mediate K63 ubiquitination of RIP1 to induce JNK 
activation. Additionally, Ubc13 has been found to act with TRAF6 to mediate non-
proteolytic ubiquitination of protein substrates, such as TRAF6 itself and TAK1, 
involved in activating the IKK complex in TLR signaling cascades37,77,78. Many 
additional examples of K63 ubiquitination in these pathways exist and interestingly, this 
regulation of signaling has been expanded and implicated in IGF and EGF growth factor 
mediated pathways37.  
The addition and removal of K63 ubiquitin marks are under tight control. The 
cleavage of K63 ubiquitin chains is achieved in part by the DUB, OTUB1, which was 
found to bind and inhibit the activty of Ubc1367-69,75,76. Various mouse models have been 
developed in order to study the regulation of K63 ubiquitin as well. Interestingly, 
whereas Ubc13 knockout mice show significantly impaired K63 ubiquitination, the fact 
that this posttranslational modication is not completely abolished leaves open the 
possibility that more E2 conjugating enzymes that can make K63 chains may exist67-
69,75,76. Expanding the studies of K63 ubiquitination to other signaling cascades can help 
shed light on additional mechanisms of regulation in a multitude of pathways. 
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G-Protein Pathway Suppressor 2 (GPS2) 
Overview and initial discovery  
G-protein pathway suppressor 2 (GPS2) is a 37 kDa, relatively unstructured and 
ubiquitously expressed protein. It is found localized in the cytoplasm, nucleus, and, more 
recently, in mitochondria. Total body knockout of GPS2 is embryonic lethal, with mice 
only surviving through embryonic development days E9.5- E10.580. These data suggests 
that GPS2 is an extremely important protein warranting further studies to understand its 
full function.  
GPS2 was originally discovered in 1996 in a screen interrogating suppressors of 
signal transduction in the yeast pheromone response pathway81-83. In this work, human 
GPS2 was identified as a potent suppressor of RAS- and MAPK-mediated signaling 
pathways, resulting in compromised JNK activity81. Through an additional independent 
yeast- two hybrid screen, GPS2 was identified to interact with Human T lymphotropic 
virus type 1 Tax oncoprotein and was found as a suppressor of TAX- mediated TNFa 
signaling. In this study, overexpression of GPS2 was again found to potently suppress 
JNK activation83. These studies were the first to suggest that GPS2 could play an 
important role in signal transduction.  
Follow up studies identifying GPS2 nuclear localization instead focused on GPS2 
function in regulating gene transcription and other nuclear functions79,84-86. Work from 
various laboratories, for example, indicate that nuclear GPS2 acts as a transcriptional 
coactivator for several nuclear receptors and transcription factors79,87-93. This function of 
GPS2 has been implicated in regulating cell proliferation as well as DNA damage 
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repair90,94,95. GPS2 transcriptional activating function was also found to play a role in 
viral transcription and replication. Additionally, the discovery of GPS2 as a fundamental 
subunit of NCoR/SMRT corepressor complexes suggested that nuclear GPS2 could 
function as a corepressor as well93.  
GPS2 cytoplasmic function has been further elucidated since the original work 
uncovering GPS2 potential role in signal transduction. Our lab has reported a number of 
distinct, but coordinated functions for GPS2 in the cytosol as a regulator of pro-
inflammatory response pathways, that appear to be conserved in adipose tissue, 
macrophages and B cells84-86. Notably, our work suggests that both nuclear and cytosolic 
functions are based on GPS2-mediated inhibition of K63 ubiquitination events79,84-86. 
Overall, the cumulative, initial studies of GPS2 imply it is an exceedingly vital protein in 
regulating both transcriptional activation and repression as well as mediating important 
signal transduction pathways.  
GPS2 role in mediating transcriptional repression  
GPS2 has been identified as an fundamental component of corepressor 
transcriptional complexes, suggesting it plays a role in transcriptional repression. A 
report was published in 2002 first showing that GPS2 was an integral member of the 
NCoR corepressor complex93. GPS2 was identified by mass spectrometry as a 
stoichiometric subunit of the NCoR-HDAC3 complex via interaction with the repressor 
domain (RD1) of NCoR, as well as interactions with TBL1 and TBLR193. This work 
showed that promoter bound GPS2 was able to repress transcription by its association 
with the NCoR complex and suggested that GPS2-mediated inhibition of JNK activation 
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was a result of GPS2-NCoR transcriptional repression93. Just as GPS2 was found to be an 
integral component of the NCoR corepressor complex, it was also shown that GPS2 was 
a fundamental subunit of the SMRT corepressor complex, which functions very similarly 
to NCoR through recruitment of HDACs90. In this work GPS2 was shown to be an 
important component of this complex and functionally involved in ERa-mediated 
transcriptional repression90.  
The structural interaction of the NCoR/SMRT transcriptional repressor complex 
was investigated revealing how GPS2 how binds in this complex. SMRT and GPS2 form 
an anti-parallel coiled coil in which amino acids 167-207 are sufficient to interact with 
amino acids 53-90 of GPS296. In turn, TBL1 crystal structure revealed that TBL1 N 
terminal domain dimerized and amino acids 1-71 of each TBL1 protein could interact 
with amino acids 227-297 of SMRT and amino acids 1-60 of GPS2, each containing a 
short helical sequence96.  
In support of the role of GPS2 in mediating transcriptional repression, recent 
studies indicate that downregulation of GPS2 with the associated corepressor SMRT in 
adipose tissue of obese individuals plays a critical role in the upregulation of a pro-
inflammatory gene program97. Additionally, it was suggested that GPS2 may play a role 
in transrepression of PPARg and LXR but more mechanistic data is required to identify 
GPS2 exact role in repression in these model systems80,91. This evidence along with data 
showing GPS2 direct interaction within the NCoR/SMRT complex supports the idea that 
GPS2 is involved with transcriptional repression although direct evidence for GPS2 alone 
acting to control repression remains to be further elucidated. 
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GPS2 role in mediating transcriptional activation  
Despite data showing that GPS2 may play a role in transcriptional repression, 
more evidence has suggested that GPS2 plays a role in transcriptional activation with 
various nuclear receptors and transcription factors82,87,88,91,95,98-104. These initial studies 
led the groundwork for mechanistic studies indeed showing GPS2 plays a crucial role in 
transcriptional activation of FXR, LXR, and PPARg79,89,105. 
The first evidence for the role of GPS2 as a transcriptional coactivator was 
suggested in greater mechanistic detail in studies of bile acid biosynthesis in liver cells105. 
It was found that GPS2 is a cofactor for SHP, a known physiological repressor of bile 
acid biosynthesis. By interacting with SHP and additional binding partners, LRH-1, 
HNFa, and FXR, GPS2 was found differentially regulating the transcription of the genes, 
CYP7A1 and CYP8B1, key enzymes involved in hepatic bile acid synthesis105. 
Specifically, GPS2 was found to modulate SHP repression by enhancing interactions with 
NCoR-HDAC3 repressor complex. GPS2 was shown to differentially regulate CYP7A1 
and CYP8B1, which was found to be a result of GPS2 repressor of the nuclear receptor 
LRH-1 on CYP7A1 and GPS2 enhancement of HNF4a on CYP8B1. It was observed that 
GPS2 interacted with FXR and potentiated FXR-mediated transcription of the CYP8B1 
promoter. It was implied that CYP8B1 transcriptional induction is ligand-dependent and 
requires GPS2 to induce enhancer-promoter communication105. This report was the first 
to succinctly explore the differential gene-specific repressor versus activator functions of 
GPS2.  
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Because GPS2 was shown to function in cholesterol homeostasis in liver by 
regulating bile acid biosynthesis via target gene specific repressor as well as activator 
roles, an additional report then investigated the function of GPS2 in regulating LXR-
mediated cholesterol efflux in liver and macrophages89. This work showed that GPS2 is 
selectively required for LXR activation of the cholesterol efflux gene, ABCG1, while not 
affecting other LXR-dependent cholesterol transport genes. Whereas in the case of the 
gene ABCA1, GPS2 was present on the promoter in the unliganded state and was 
dismissed upon ligand binding; in the case of ABCG1, GPS2 recruitment to the promoter 
was dependent on ligand binding suggesting that GPS2 functions as a coactivator for 
LXR on this specific gene. In this case, GPS2 was found to bind the heterodimer 
LXR/RXR on the ABCG1 promoter. As was suggested in the case of CYP8B1, GPS2 
was proposed to mediate ABCG1 promoter enhancer looping and communication upon 
LXR ligand activation of the gene. Lastly, this work showed that GPS2 was required to 
initiate H3K9 demethylation of the ABCG1 gene89.  
GPS2 has been shown to be involved in the regulation of the nuclear receptor, 
PPARg79,80 whereby the NCoR/SMRT corepressor complex was shown to repress PPARγ 
gene expression and 3T3-L1 cells devoid of NCoR/SMRT had an increase in adipogenic 
differentiation80,106. As expected since GPS2 plays a key role in the regulation of PPARg, 
GPS2 has been implicated in various studies in the regulation of adipogenesis84,107. 
Interestingly, however, our lab discovered a novel mechanism of GPS2 regulation of 
PPARg, distinct from its role with the NCoR/SMRT corepressor complex. GPS2 was 
shown to act as a pioneering and coactivating factor for PPARg recruitment on a subset of  
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Figure 1.6 –Model of GPS2-mediated regulation of PPARg recruitment in 
adipocytes. 
GPS2 inhibition of Ubc13/RNF8 results in chromatin remodeling events to allow the 
biding of PPARg on promoters to regulate a subset of target genes. This figure was 
adapted from: Cardamone, M. D. et al. GPS2/KDM4A pioneering activity regulates 
promoter-specific recruitment of PPARgamma. Cell reports 8, 163-176, 
doi:10.1016/j.celrep.2014.05.041 (2014).79 
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target genes in which PPARg binding is necessary on promoters, rather than on 
enhancers79. In this work it was revealed that GPS2 can stabilize KDM4A, an H3K9 
histone demethylase, by inhibiting Ubc13 and RNF8 ubiquitination. This priming of the 
chromatin environment was required for broad PPARg promoter-specific binding79. This 
regulatory strategy was found to be required for the regulation of a select PPARg 
transcriptional program that included the rate-determining enzymes of lipolysis, ATGL 
and HSL (Figure 1.6) 79. 
 In agreement with this mechanistic study dissecting how GPS2 regulates PPARg 
recruitment and adipocyte function, GPS2 has been shown to play an important role in 
the regulation of lipid metabolism in vivo as well. Transgenic mice overexpressing GPS2 
in AT were found to have increased expression of ATGL and HSL, both at the mRNA 
and protein level79. This in turn led to increased phosphorylation and activation of HSL,  
as a marker of lipolysis. The white adipose tissue also exhibited an enhanced response to 
isoproterenol induced lipolysis79. This mechanism led to smaller adipocytes in the 
adipose tissue depots from TG mice. These data suggest that GPS2 plays an important 
role in regulating lipid metabolism in adipose tissue however the complete understanding 
of this role in vivo remains to be elucidated.  
The role of cytoplasmic GPS2 in regulating inflammation 
In the initial discovery of GPS2, it was noted that GPS2 could potently suppress 
the activity of JNK, an important mediator of downstream inflammatory signaling 
cascades81,83. Accordingly, subsequent studies have discovered numerous roles of GPS2 
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in regulating inflammation in various cell types including adipose tissue, macrophages, 
and B cells84,91,97,108.  
In particular, work by our lab uncovered a specific role for GPS2 outside the 
nucleus in the regulation of inflammatory signal transduction.  GPS2 can interact with 
TRAF2/Ubc13 K63 ubiquitination machinery to affect the activation of the TNFa 
signaling pathway (Figure 1.7A)84. GPS2 was found to regulate the activation of TNFR1 
in response to TNFa via the inhibition of JNK activation84. This mechanism led to 
hyperactivation of a proinflammatory gene transcription program in the absence of 
GPS284. Interestingly, this mechanism was found to regulate adipogenesis as well. 
Removal of GPS2 in 3T3L1 cells prior to inducing differentiation resulted in decreased 
expression of PPARg and these cells were unable to induce expression of mature 
adipogenic genes and fully undergo differentiation84. Downregulation of TRAF2 or 
treatment of GPS2 knockdown cells with a JNK inhibitor was able to rescue this 
phenotype, suggesting that unregulated inflammation, as a result of lack of GPS2, could 
negatively impact the early stages of adipocyte differentiation84. 
In continuation of this work by our lab, we studied the effect of GPS2 
overexpression in adipose tissue on inflammation in vivo. In this work addressing that 
GPS2 acts as a negative regulator of the TNFa signaling pathway, aP2-driven 
overexpression of GPS2 resulted in mice that were protected from hyperinflammatory 
signaling in the adipose tissue84. These mice on high fat diet exhibited decreased 
phosphorylation of JNK and decreased expression of inflammatory gene markers, 
resulting in improved adipose tissue insulin signaling84. Fitting with these results, it was  
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Figure 1.7 –Model of GPS2 anti-inflammatory action. 
(A) In AT, GPS2 inhibts TNFa-mediated signaling via inhibition of Ubc13/TRAF2. (B) 
GPS2 inhibition of Ubc13 modulates TLR and BCR inflammatory signaling cascades in 
B cells. This figure was adapted from Cardamone, M. D. et al. A protective strategy 
against hyperinflammatory responses requiring the nontranscriptional actions of GPS2. 
Mol Cell 46, 91-104, doi:10.1016/j.molcel.2012.01.025 (2012) and Lentucci, C. et al. 
Inhibition of Ubc13-mediated ubiquitination by GPS2 regulates multiple stages of B cell 
development. The Journal of biological chemistry, doi:10.1074/jbc.M116.755132 
(2016).84,85 
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found in human patients there was an inverse correlation between GPS2 and SMRT 
levels and inflammatory status in obese adipose tissue and this effect was found to be 
reversible with bariatric surgery97. Lack of GPS2 and SMRT in adipocytes led to 
increased pro-inflammatory gene expression and secretion of inflammatory cytokines97. 
Surprisingly, the GPS2 TG mice with decreased inflammation did not have improved 
systemic metabolic parameters, which was thought to result from an increase in 
circulating resistin and increased lipid deposition in the liver84.  
In the case of macrophages, an inverse correlation exists between GPS2 levels in 
AT macrophages and markers of inflammation with hyperglycemia in adipose tissue108. 
Macrophage specific GPS2 knockout mice exhibited a pro-inflammatory gene signature 
which was exacerbated when treated with TLR4 agonists108. This was found in part to be 
mediated by GPS2 interaction with AP-1 (c-Jun) however the cytoplasmic function of 
GPS2 was not explored in this context108. Upon high fat diet feeding, mice with GPS2  
deficiency in macrophages were found to have increased AT and systemic inflammation, 
increased macrophage infiltration in adipose tissue with a pro-inflammatory 
phenotype108. This resulted in increased liver lipid deposition, impaired glucose and 
insulin tolerance, and decreased phosphorylation and activation of AKT as a marker of 
insulin signaling108. Conversely, overexpression of GPS2 in macrophages reversed this 
phenotype108. Collectively these data point to GPS2 as a key mediator of macrophage 
inflammatory function, specifically in the context of diet-induced insulin resistance.  
 Most recently, we reported that GPS2 plays an important anti-inflammatory role 
in B cells as well. In this work, using B cell specific knockout of GPS2, it was found that 
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these mice had hyperactive TLR and BCR signaling pathways through the cytoplasmic 
function of GPS2 to inhibit Ubc13 activity (Figure 1.7B)85. Loss of GPS2 regulation of 
these pathways resulted in significantly increased pro-inflammatory gene expression85. 
GPS2 regulation of these pathways affected various stages of B cell development in 
which these pathways are critical in the development of various mature functional B cell 
populations85. Overall, the combination of these data in various tissues clearly show that 
GPS2 has a fundamental role in the regulation of signal transduction pathways that are 
central to inflammatory processes. 
GPS2 mechanism of action and regulation  
While studied in various signaling pathways, cellular locations and numerous 
processes, our lab has identified that there is one unifying function of GPS2 in all these 
various applications. GPS2 is able to endogenously inhibit the enzymatic activity of the 
E2 ubiquitin congujating enzyme, Ubc1385. Although it does not appear that GPS2 blocks 
ubiquitin charging nor mono- or di-ubiquitin formation, it seems as though GPS2 blocks 
the formation of polyubiquitin chains. This has been addressed by showing the addition 
of GPS2 blocks ubiquitin chain formation on many substrates in various 
immunoprecipitation and in vitro ubiquitination assays84,85. More thorough structural 
studies are necessary to understand the exact mechanism of how GPS2 can inhibit Ubc13.  
Further studies in trying to understand how GPS2 itself is regulated have revealed 
that GPS2 activity is mediated by posttranslational modifications, protein interactions, 
localization and a balance between stabilization and proteasomal degradation. It was 
found that the N terminal domain of GPS2 was necessary for its targeting into the 
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nucleus109. Although an identified nuclear localization sequence of GPS2 was not found 
to interfere with nuclear import, this region of GPS2 was found to interact with the N 
terminus of TBL1109. GPS2 interaction with TBL1 was found necessary for its nuclear 
localization as well as stabilization. Furthermore, it was found that GPS2 undergoes 
sumoylation at two distinct amino terminal sites, K45 and K71, by the small-ubiquitin-
like modifier, SUMO-1, and this modification could be reversed by SENP194. Certain 
evidence suggested that sumoylation was necessary for GPS2 and TBL1 binding94. 
However, more thorough studies found the mutation of these two sumoylation sites 
interupted GPS2 and TBL1 binding not because of sumoylation per se but because these 
mutation affected the proper folding of GPS2. This was proven in studies in which 
knocking down the SUMO- congujating enzyme, Ubc9, did not impair GPS2 and TBL1 
binding109.  
The stabilization of GPS2 through its interaction with TBL1 significantly 
protected GPS2 from proteasomal degradation mediated by Siah2109. GPS2 was found to 
undergo polyubiquitination in its C terminus. Interestingly, the C terminal domain of 
GPS2 and the WD40 domain in the C terminal domain of TBL1 were found to interact109. 
Various screening studies suggested that arginine residues of GPS2 underwent 
methylation110-112 and it was later discovered that these arginine residues flanked the sites 
of ubiquitination on GPS2. Specifically, it was observed that PRMT6 regulated 
methylation of GPS2 on arginine residues 312 and 323. This methylation ensured C 
terminal GPS2 and TBL1 binding, preventing proteasomal degradation of GPS2 by 
Siah2109. These data suggest that various posttranslational modifications of GPS2 
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regulate protein activity, localization and stability, however more extensive studies are 
required to reveal the full program responsible for the modulation of GPS2.  
Significance and research goals 
 Obesity has emerged as a worldwide health epidemic, particularly as a serious 
risk factor in the development of various metabolic syndromes, including T2D. More 
specifically, obesity-associated inflammation is widely recognized as a critical factor in 
the development of insulin resistance leading to T2D. However, anti-inflammatory drug 
therapies have proven unsuccessful in treating these metabolic syndromes. In addition, 
recent reports have shown that healthy AT expansion, which results in adequate lipid 
storage in this tissue and not in other peripheral organs, can abrogate the development of 
insulin resistance. Together, these observations raise the fundamental question of whether 
inhibiting inflammation is an appropriate approach in the attempt to develop therapeutics 
and treat insulin resistance or whether the focus for clinical therapies should 
concentration on hijacking mechanisms of healthy AT expansion for the prevention of 
this disease.  
The research goal of this project was to understand the intersection as well as 
delineation between lipid metabolism and inflammation in AT under homeostatic and 
dietary stress conditions and how they may be modulated to alleviate insulin resistance. 
Since GPS2 has recently emerged as an critical, novel regulator in metabolic organs, we 
characterized the in vivo function of GPS2 using the adipocyte-specific GPS2 knockout 
mouse model to explore the critical role of GPS2 in regulating lipid metabolism and 
obesity-induced inflammation in AT. Based on previous data, we hypothesized that the 
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imbalance in the flux between fatty acid mobilization and utilization along with proper 
remodeling and expansion of AT, potentially through assistance from infiltrated immune 
cells, can result in an improved metabolic status of GPS2-AKO mice. Importantly, this 
hypothesis implicates an unexpected uncoupling between lipid metabolism and 
inflammation within AT under conditions of excessive nutrient load, thus suggesting that 
inhibiting inflammation in the context of obesity may not be the ideal strategy to 
ameliorate metabolic dysfunction. This project facilitates a strong approach to gain a 
better understanding of the casual relationship between obesity, inflammation, and insulin 
resistance.  
In order to test our hypothesis, we first characterized the effect of GPS2 on the 
insulin signaling pathway and lipid storage capacity of white adipocytes. The goal of this 
part of the project was to elucidate the mechanisms underlying GPS2 regulation of lipid 
flux in adipocytes. We discovered that modulating GPS2 can affect the lipid storage 
capacity of adipocytes by modulating AKT activation affecting pathways involved in 
lipid storage and mobilization. Additionally, we illustrated the effects of GPS2 knockout 
on mitochondrial function and brown fat activity. Secondly, we aimed to understand the 
contribution of AT inflammation to the overall metabolic profile of GPS2 AKO mice. We 
revealed that despite increased obeisty and AT inflammation, GPS2-AKO mice remained 
metabolically healthy. These data suggest that an uncoupling of inflammation with 
whole-body metabolic status may exist if continued healthy expansion to extend the 
maximum storage capacity of the adipose tissue can be accomplished.  
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This thesis project represents an innovative means to comprehensively investigate 
the complex relationship between insulin signaling regulated lipid flux and AT 
inflammation in the development of insulin resistance, with important implications for 
the discovery and design of effective therapeutic approaches against metabolic diseases, 
especially T2D. 
 
		
43 
CHAPTER TWO –MATERIALS AND METHODS 
Animal studies 
Fat-specific GPS2 knockout mice (GPS2-AKO) were generated using a cre/lox 
approach and maintained on a mixed 129sv/C57BL6J background. Conditional Gps2 
floxed mice were generated by inGenious Targeting Laboratory.  The 9.52 kb region used 
to construct the targeting vector was first sub cloned from a positively identified 
C57BL/6 (RP23: 91G16) BAC clone into a ~2.4kb backbone vector (pSP72, Promega) 
containing an ampicillin selection cassette. The total size of the targeting construct 
(including vector backbone and Neo cassette) is ~13.62kb. The region was designed such 
that the short homology arm (SA) extends about 2.55kb 3’ to exon 6. The long homology 
arm (LA) ends 5’ to exon 3 and is 6.07kb long. A pGK-gb2 loxP/FRT Neo cassette is 
inserted on the 3’ side of exon 6 and the single loxP site is inserted 5’ of exon 3. The 
target region is 0.90 kb and includes exon 3-6. The targeting vector was linearized by 
NotI and then transfected by electroporation of BA1 (C57BL/6x129/SvEv) hybrid 
embryonic stem cells. After selection with G418 antibiotic, surviving clones were 
expanded for PCR analysis to identify recombinant ES clones and control for retention of 
the third LoxP site. Secondary confirmation of positive clones was performed by 
Southern Blotting analysis prior to microinjection into C57BL/6 blastocysts. Resulting 
chimeras with a high percentage agouti coat color were mated to wild-type C57BL/6J 
mice to generate F1 heterozygous offspring. The Neo cassette was excised by crossing 
with FLP mice (Jackson Laboratories) to generate F2 heterozygous mice with Neo 
deletion in somatic cells and F3 heterozygous mice with Neo deletion in germ cells. 
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Adipose tissue specific deletion was achieved by crossing Gps2flox/flox mice with 
heterozygous Adipoq-Cre C57BL/6J transgenic mice expressing Cre recombinase under 
control of the adiponectin promoter 113. Male mice and littermate controls were used for 
all experiments. Mice were maintained on standard laboratory chow diet in temperature 
controlled facility on a 12-hour light/dark cycle.  
Homozygous Gps2flox/flox mice were then used for crossing with heterozygous 
129sv CD19-cre mice 114(Jackson Laboratories) to create B cell-specific GPS2 knockout 
mice. The CD19 promoter specifically directs expression at the earliest stages and 
throughout B-lymphocyte development and differentiation114. Because the Cre cassette is 
inserted into exon 2 of CD19 gene, functionally disrupting the gene, homozygous CD19-
cre mice are CD19-deficient. However, heterozygous mice are phenotypically normal and 
can be used for specific deletion of floxed targets in B-lymphocytes 114. Wild-type mice 
used as control for all analyses presented here were littermates Gps2flox/flox/CD19Cre-. All 
experiments are done with mice 10 to 16 wks old. 
Genotypes of mice were confirmed by PCR for the two floxed GPS2 alleles and 
for the presence of CRE using the primers listed in Table 3.  
Mice used for HFD studies were placed on 45% HFD (Research Diet) at 6-8 
weeks of age. Body weights were measured weekly for the 16-week diet regiment or 
under chow conditions. Weight measurements were also taken after an overnight fast in 
chow mice 4-6 months of age and at time of sacrifice for all mice.  
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All animal studies were approved by the Boston University Institutional Animal 
Care and Use Committee (IACUC) and performed in strict accordance of NIH guidelines 
for animal care.  
Tissue fractionation, primary cell culturing and differentiation 
Tissue fractionation of primary mature adipocytes and the stromal vascular 
fraction (SVF) were isolated from adipose tissue depots using collagenase type I/dispase 
II (Fisher) digestion in 4% BSA (Sigma) Kreb-Ringer HEPES (KRH) ( 1.3M NaCl, 4.7 
mM KCl, 1.24 mM MgSO4, 3.3 mM CaCl2-2H2O, with 1X HEPES/PHOS) buffer for 
45 minutes, then filtered and adipocytes were separated by floating and washed 3 times in 
1% BSA KRH buffer prior to resuspension in lysis buffer for protein extraction or Trizol 
for RNA analysis. 
The SVF was spun down at 900 rpm for 10 minutes. Cells were cultured in high 
glucose DMEM with 10% fetal bovine serum (Hyclone) and 1X pen/strep until confluent. 
Two days after confluence, in vitro adipogenic differentiation was induced using a 
standard insulin (Sigma), IBMX (Sigma), and DEX (Sigma) cocktail for WAT and the 
same cocktail supplemented with 10 uM T3 for BAT depots for 12 additional days. 
Maintenance media was replenished every two days.  
Body composition analysis and metabolic testing 
Mice body composition was assessed by non-invasive MRI scanning on an 
EchoMRI 700 (BUSM Metabolic Phenotyping core). Glucose Tolerance Test (GTT) and 
Insulin Tolerance Test (ITT) were performed according to established protocols 115. Mice 
were starved overnight or 4-6 hours for GTT and ITT, respectively. Blood glucose levels 
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were measured, at the described time points after glucose (Sigma) (1.5mg/g body weight) 
or insulin (Humulin R, Lilly) (0.5U/kg body weight) i.p. injection with an insulin syringe 
(BD), from tail nicking using a OneTouch Ultra meter. For HFD studies, GTT’s and 
ITT’s were performed at 14 weeks and 15 weeks of diet treatment, respectively. 
Plasma collection and assays and ELISAs 
Mice were fasted overnight and terminally anesthetized using 2-bromo-2-chloro-
1,1,1-trifluoroethane (Sigma). 26 gauge syringes were coated with 0.1M EDTA and 
plasma was collected by cardiac puncture into tubes with 100 uL 0.1M EDTA. Samples 
were kept on ice then spun at maximum speed at RT for 5 minutes. Plasma fraction was 
removed and used for assays and ELISAs. MCP1, Adiponectin, Leptin, and Insulin were 
profiled using Milliplex Multiplex Assays (Millipore, BUSM Analytical Core). 
Additional plasma Insulin levels were measured using the Rat/Mouse Insulin ELISA kit 
(Millipore) according to manufacturer’s instructions. Plasma glycerol levels were 
measured using the Free Glycerol Determination Kit (Sigma) and Plasma FFA levels 
were measured using Free Fatty Acid Fluorometric Assay Kit (Cayman Chemical) 
following manufacturer’s instructions.  
Lipolysis assays 
In vitro differentiated cells were washed with 1X PBS (137 mM NaCl,5.4 mM 
KCl, 16.2 mM Na2HPO4, 2.9 mM KH2PO4) then incubated with high glucose DMEM 
+2% BSA without serum for 2-3 hours. Cells were washed with phenol-free DMEM 
without serum then incubated in serum free phenol free DMEM +2%FFA- free BSA 
(Sigma) with or without 10uM isoproterenol (Sigma) for 1 hour. Media was collected for 
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measuring the released glycerol using the free glycerol reagent (Sigma). Glycerol 
concentrations were calculated from a standard curve and values normalized to protein 
concentration per well assessed by Bradford assay (Bio-Rad) as described above. Results 
shown include data points from three independent experiments, each time the assay was 
performed with technical triplicates. 
Staining 
Upon harvesting, adipose tissue depot and liver tissues were incubated at 4°C in 
Z-fix solution (Anatech LTD) overnight. Tissues were then transferred to 70% ethanol, 
paraffin embedded, sectioned, and stained with hematoxylin & eosin (Tuft Pathology 
Core/BNORC Adipose Biology Core). Imaging of adipocyte cell size was performed as 
described 116,117.  
In vitro differentiated brown adipocytes were fixed in 10% formalin at room 
temperature for 30 minutes. Oil Red O (ORO) stock solution was prepared by adding 
0.3G ORO powder (Alfa Aesar) in 100 mL isopropanol. Cells were washed 2X with 
1XPBS then incubated in Oil Red O (ORO) working solution (3 parts ORO stock with 2 
parts water and filtered through .2 uM filter) for 5 minutes. Stain was removed by 
washing with 60% isopropanol then with distilled water until excess stain was removed 
and visualized immediately by microscopy.  
Immunofluorescence for macrophage staining was performed on fixed tissue 
sections. Sections were deparaffinized by washing 3X 5 minutes in xylene in a glass 
container. Slides were then washed as follows: 2X 5 minutes in 100% ethanol, 2X 5 
minutes in 95% ethanol, 1X 5 minutes in 80% ethanol, 1X 5 minutes in 70% ethanol 1X 
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5 minutes in 50% ethanol, and 2X 5 minutes in dH2O. Slides were placed into a wash 
container with antigen retrieval buffer (10 mM sodium citrate, 0.05% Tween 20, pH6) 
and heated on full power in a microwave until boil began. Power was slowly reduced in 
microwave for 9 minutes and slides were cooled for 20 minutes at room temperature then 
washed 3X 5 minutes in water. Slides were drained and a hydrophobic barrier was 
created around each tissue section using an ImmEdge pen. Slides were washed with 1X 
PBS for 5 minutes then placed into a wash container with permeabilization buffer 
(0.2%Triton X-100 in PBS) for 45 minutes at room temperature. Slides were again 
washed with 1X PBS and blocked in blocking buffer (0.5% BSA, 1:1000 donkey serum 
in PBS) for 1 hour at room temperature in a humidified chamber. Slides were washed 3X 
for 5 minutes in 1X PBS and primary conjugated antibody (Alexa Fluor 647 anti-mouse 
Mac-2, Biolegend) was added and incubated overnight in a humidified chamber at 4C. 
Slides were washed 3X 5minutes in 1X PBS then mounted with coverslips using 
mounting media containing DAPI. Slides were stored at 4C in the dark and then imaged 
by fluorescent microscopy.  
Cell culture and isolation 
3T3-L1 preadipocytes (American Type Culture Collection) were cultured in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM) (Corning) with 10% fetal calf 
serum (Hyclone) under 5% CO2. Cell lines were trypsinized using 0.25% Trypsin 
(Corning) and split twice weekly prior to reaching confluence. Cells were serum starved 
overnight prior to 100nM insulin (Life Technologies) treatment for described time points.  
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Transient Transfection 
Cells were transfected using Lipofectamine2000 (Invitrogen) and Opti-MEM 
reduced serum media (Thermo Fisher Scientific) according to each manufacturer’s 
instructions. The following siRNA’s were used: MISSION siRNA universal negative 
control (Sigma), siGPS2 (#s80309, 20nM, Ambion), siUBC13 (#s123784, 20nM, 
Ambion) with more detailed information found in Table 1.  
Target RNA Species Sequence Source Concentration 
CTRL siRNA Mouse MISSION siRNA universal negative control Sigma 20 nM 
GPS2 siRNA Mouse CCUGCAGUGCAGUACCUAUtt Ambion 20 nM 
Ubc13 siRNA Mouse GCCGAGCAAUGGAAGACCAtt Ambion 20 nM 
Table 1. siRNA sequences. 
Site-directed mutagenesis and AKT cell lines 
AKT plasmid constructs were kindly provided from the Guertin Lab and site-
specific mutations were created using the QuikChange II XL Site- directed Mutagenesis 
Kit (Agilent) then shipped back to the Guertin Lab for reexpression in AKT null cell 
lines.  
AKT null cells are UBC-Cre ERT2; AKT1 fl/fl, AKT2 fl/fl in an AKT3 KO 
background. To generate this line, primary brown adipocyte precursors (bAPC) cells 
were isolated from P1 neonates and immortalized with pBabe-SV40 Large T antigen. To 
induce AKT1 and AKT2 deletion UBC-Cre ERT2; AKT1 fl/fl, AKT2 fl/fl cells were 
treated on 2 consecutive days with 1uM 4-hydroxy tamoxifen and on the 3rd day the 
media was changed to regular media to allow protein turnover. On the 4th day, cells were 
plated during the morning at 80% confluence, serum removed later in the day for 
overnight starvation prior to 15’ insulin treatment (150nM) and protein extraction. 
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Protein isolation, immunoprecipitation and western blot analysis 
Whole cell extracts were prepared from cultured cells by homogenization in lysis 
buffer (50 mM Tris HCl pH 8, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40) supplemented 
with 0.1mM PMSF, 10mM NEM (Thermo fisher scientific), 1X protease inhibitors 
(Pierce) and 1X phosphatase inhibitors (Pierce). Cells were resuspended in lysis buffer 
for 20 minutes on ice then spun at maximum speed for 10 minutes at 4C. Supernatant was 
then removed. WCE from tissue were homogenized using 1 mm ZrOx beads in lysis 
buffer (50mM Tris-Hcl pH8, 300 mM NaCl, 5 mM EDTA, 0.1mM PMSF, 10 mM NEM, 
1X protease inhibitor cocktail, 1X phosphatase inhibitor cocktail) in the Bullet Blender 
(Next Advance, Inc) at setting 9 for 5 minutes. Homogenates were then spun 2X 5 
minutes at 1000 RPM at 4C to remove lipids then rotated for 10 minutes in lysis buffer 
supplemented with 2% Triton. Samples were spun at maximum speed for 10 minutes at 
4C and the supernatant was collected. All protein concentrations were analyzed using the 
Bradford assay (Bio-Rad) to a BSA standard curve and normalized for protein loading. 
 Immunoprecipitation were performed on whole cell lysates upon incubation of 
indicated antibodies overnight followed by collection of immune complexes with 50 uL 
Protein A-sepharose 4B conjugate (Thermo fisher scientific). Beads were precipitated by 
centrifugation at 1000 RPM for 1 minute and washed 3X with IPH buffer (50 mM Tris 
(pH 7.4), 300 mM NaCl, 1 mM EDTA, 0.1% Triton X-100) and eluted in NuPAGE LDS 
sample buffer (Life Technologies) substituted with 100 mM DTT for analysis. 
Extracts were boiled in NuPAGE LDS sample buffer for 10 minutes and loaded in 
10% Mini-PROTEAN TGX gels (Bio-Rad) in SDS-PAGE running buffer (25 mM Tris, 
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192 mM glycine, 0.1% SDS) (Boston Bioproducts) at 180 V for 1 hour. Proteins were 
immobilized onto PVDF membranes (Millipore) by transferring in 1X transfer buffer (25 
mM Tris, 200 mM glycine, 20% methanol) at 100 V for 45 minutes. Membranes were 
then blocked in 5% BSA (Fisher) diluted in PBS-T (137 mM NaCl,5.4 mM KCl, 16.2 
mM Na2HPO4, 2.9 mM KH2PO4, 0.1% Tween-20) for 1 hour at room temperature. 
Membranes were incubated in primary antibody overnight at 4°C. The following day 
membranes were washed 3 times 10 minutes in PBS-T. Membranes in unconjugated 
primary antibodies were incubated in secondary antibody for 1 hour at room temperature, 
washed again 3 times 10 minutes in TBS- T and immediately visualized. All blots were 
visualized using Clarity Western ECL Substrate (Bio-Rad), exposed for 1 to 500 seconds, 
and captured on Chemi DocTM XRS+ imaging station (Bio-Rad) using Image Lab 
software (Bio-Rad). Expressed proteins were compared to Precision Plus Protein 
Standard protein ladder (Bio-Rad) to determine size. All antibodies are outlined in Table 
2.  
Specificity Species Source Catalog # Application Concentration 
Anti-GPS2 N term rabbit N/A N/A WB 1:1000 
Anti-GPS2 C term rabbit N/A N/A WB 1:1000 
Anti-GPS2 C term rabbit N/A N/A ChIP 5uL per IP 
Anti-AKT rabbit Cell Signaling #9272 WB 1:1000 
Anti-AKT rabbit Cell Signaling #9272 IP 5 uL per IP 
Anti-P-AKT 
ser473 
rabbit Cell Signaling #9271 WB 1:500 
Anti-P-AKT 
thr308 
rabbit Cell Signaling #9275 WB 1:500 
Anti- 
Polyubiquitin 
K63-linkage-
specific 
mouse Enzo Lifescience HWA4C4 WB 1:500 
Anti-AKT1 rabbit Cell Signaling #2938 WB 1:1000 
Anti-AKT2 
(D6G4) 
rabbit Cell Signaling #3063 WB 1:1000 
Anti-HA mouse Cell Signaling #2367 WB 1:1000 
Anti-b Tubulin mouse Sigma T4026 WB 1:2000 
Anti-PRAS 
(D23C7) XP 
rabbit Cell Signaling #2691 WB 1:2000 
Anti-P-PRAS 
Thr246 
rabbit Cell Signaling #2997 WB 1:2000 
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Anti-rpS6 rabbit Cell Signaling #2217 WB 1:1000 
Anti-P-rpS6 rabbit Cell Signaling #4858 WB 1:1000 
Anti-GSK3b rabbit Cell Signaling #9315 WB 1:1000 
Anti-P-GSK3b 
ser9 
rabbit Cell Signaling #9322 WB 1:1000 
Anti-PKA R2 rabbit Abcam #ab38949 WB 1:1000 
Anti-P-PKA R2 
ser99 
rabbit Abcam #ab32390 WB 1:1000 
Anti-P-(ser/thr) 
PKA substrates 
rabbit Cell Signaling #9621 WB 1:1000 
Anti-JNK rabbit Santa Cruz #sc-571 WB 1:1000 
Anti-P-JNK 
thr183/tyr185 
rabbit Cell Signaling #4668 WB 1:1000 
Anti-ATGL rabbit Cell Signaling  WB 1:1000 
Anti-HSL rabbit Cell Signaling #4107S WB 1:1000 
Anti-P-HSL 
ser563 
rabbit Cell Signaling #4139 WB 1:1000 
Anti-ACC rabbit Cell Signaling #3676 WB 1:1000 
Anti-P-ACC ser79 rabbit Cell Signaling #3661 WB 1:1000 
Anti-AMPK rabbit Cell Signaling #2603 WB 1:1000 
Anti-P-AMPK 
thr172 
rabbit Cell Signaling #2535 WB 1:1000 
Anti-FOXO1 rabbit Abcam #ab39670 WB 1:1000 
Anti-FOXO1 rabbit Abcam #ab39670 ChIP 2 uL per IP 
Anti-P-FOXO1 rabbit Cell Signaling #2599S WB 1:1000 
Anti-OXPHOS mouse Abcam #MS604 WB 1:500 
Anti-HSP70 mouse Thermo Scientific #MA3-028 WB 1:1000 
Anti-COX2 mouse Abcam #ab110258 WB 1:1000 
Table 2. Table of antibodies. 
Anti-GPS2-N antibody was generated in rabbit against a specific peptide 
representing aa 1-11.  
RNA isolation and gene expression analysis 
Total RNA was extracted from flash frozen tissue. Tissue was homogenized in 1 
mL Trizol reagent (Sigma) with RNase free 1mm zirconium oxide beads using a Bullet 
Blender. Samples were spun at 12000 X g for 10 minutes at 4C. Supernatant was added 
to a fresh tube and 200 uL chloroform was added. Samples were shaken by hand for 15 
seconds then centrifuged at 12000 X g for 15 minutes at 4C. The aqueous phase was 
removed in then total RNA was purified using RNeasy plus mini columns (Qiagen).  
Total RNA extracted from cultured cells or primary adipocytes was purified using 
RNeasy plus mini columns (Qiagen). 1ug of RNA was reverse transcribed using the 
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iScript cDNA Synthesis System (Bio-Rad) according to manufacturer’s instructions. 
Quantitative PCR was performed using Fast SYBR Master Mix (Applied Biosystems) 
and measured on the ViiA 7 real time PCR system (Applied Biosystems). Transcript 
levels were analyzed using ΔΔCT method and normalized to the housekeeping gene, 
Cyclophilin A. Primer sequences are outlined in Table 3. All experiments were 
performed in triplicate and statistical significance was calculated by two-tailed Student’s 
t test.  
Target Species Application Forward Reverse 
UBC13 Mouse RT-qPCR TGAGAGCAACGCCCGTTATT GGTCTTCCATTGCTCGGCTA 
GPS2 Mouse RT-qPCR AGGAAGAAAAACGGAGGCGAAA CCGTCAGGCTCTGCTGGTATG 
GPS2 Mouse PCR GAAGGCCTCGGAGAAAGC CTGGACTGCCTTGGAATTGT 
CYCLO A Mouse RT-qPCR AGCACTGGGGAGAAAGGATT CATGCCTTCTTTCACCTTCC 
CEBPB Mouse RT-qPCR ATGCAATCCGGATCAAACG CCGCAGGAACATCTTTAAGG 
PPARG Mouse RT-qPCR TCTGTGGGGATAAAGCATCAGG CGGCAGTTAAGATCACACCTATCA 
AP2 Mouse RT-qPCR TGATGCCTTTGTGGGAACCT GCTTGTCACCATCTCGTTTTCTCT 
ADIPOQ Mouse RT-qPCR GGAACTTGTGCAGGTTGGAT GCTTCTCCAGGCTCTCCTTT 
ATGL Mouse RT-qPCR GCCATGATGGTGCCCTATAC AATTTCCTCTTGGCCCTCAT 
HSL Mouse RT-qPCR GGCCGTTCCTGCAGACTCTC GAGGGAACTGGCGGTCACAC 
ACACA Mouse RT-qPCR TACTGCCATCCCATGTGCTA TAGCTTCCAGGAGCAGTCGT 
AGPAT2 Mouse RT-qPCR AGCGGACAGAAGAAACTGGA TGAAGTAGACACCCCCAAGG 
DGAT1 Mouse RT-qPCR CCAACCATCTGATCTGGCTTA CACTTGTGCACGGGGATAT 
DGAT2 Mouse RT-qPCR TCGCGAGTACCTGATGTCTG CTTCAGGGTGACTGCGTTCT 
FASN Mouse RT-qPCR AGATGAAGGTGGCAGAGGTG TGCTGCAGTTTGGTCTGAAC 
13/14 Mouse PCR CTCTGCACCGGCACATCATGATG ATCAGAACGGGGAAGTGGCAA 
40/41 Mouse PCR TGACAGAGCCAAGCAGATGT TTGTCCATGTTCTGGGGTTC 
CRE Mouse PCR AGCGATGGATTTCCGTCT CACCAGCTTGCATGATCTCC 
CD11B Mouse RT-qPCR CTTCTGGTCACAGCCCTAGC TGGACCACACTCTGTCCAAA 
F4/80 Mouse RT-qPCR GGTTTGAGCTCAGCAAGGAG CCTCTGGCTGCCAAGTTAAT 
CD11C Mouse RT-qPCR TGGATGCAGAGAAGCTGACA CAGTTGCCTGTGTGATAGCC 
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Il6 Mouse RT-qPCR CAAAGCCAGAGTCCTTCAGAG TGGTCCTTAGCCACTCCTTC 
MCP1 Mouse RT-qPCR CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
CD206 Mouse RT-qPCR AACATTGGGCAGAAGGAGTG GCCTCCAAATCACTTGCTGT 
CD301 Mouse RT-qPCR TGGCCTGAAGCTGACAAGTA TTCTCAAAGTCGGTCCCATC 
chREBP Mouse RT-qPCR CAACCACGCTTCAGAAGACA ATCAAACATGTCCCGCATCT 
SREBP1C Mouse RT-qPCR GTACCTGCGGGACAGCTTAG GGTACCGTGAGCTACCTGGA 
FBP1 Mouse RT-qPCR TGAGAAGGATGCTCTGCAGC TGACACCACAATCCATGGCA 
G6PC Mouse RT-qPCR ATTGCTGACCTGAGGAACGC GGTCTCACAGGTGACAGGGA 
PEPCK Mouse RT-qPCR CATCCCCAAAACTGGCCTCA TTCATGCACCCTGGGAACCT 
TNF Mouse RT-qPCR CCACCACGCTCTTCTGTCTA GTGGGTGAGGAGCACGTAGT 
ARG1 Mouse RT-qPCR AACACTCCCCTGACAACCAG GCAAGCCAATGTACACGATG 
IL10 Mouse RT-qPCR CCAAGCCTTATCGGAAATGA TTTTCACAGGGGAGAAATCG 
SCD1 Mouse RT-qPCR CTGACCTGAAAGCCGAGAAG GCGTTGAGCACCAGAGTGTA 
BLNK1 Mouse RT-qPCR CGGTTCCAGACATGTCCTCT GCCTCAGTGGCTTCATTCAT 
RAG1 Mouse RT-qPCR TTCCTCAGAGGGGAAACCTT TGGAGTTTCAGTGCTCGTTG 
RAG2 Mouse RT-qPCR AGCATGGGTGTTCTCTTTGG AACATGGGGTAGGCAGTCAG 
FOXO1 Mouse RT-qPCR TATTGAGCGCTTGGACTGTG TTTGGTTGGGCAACACATTA 
BLNK1 Mouse ChIP TAAGGCTCTGGCCTCAAGAA CTCCCTGGATCACATGACCT 
RAG1 Mouse ChIP CGATGCCACAGAGATAGCAA GGGTCTGCTGGTCTGTGATT 
RAG2 Mouse ChIP AGTGACTCTTCCCCAAGTGC TCTGCCCTCTTGTAGCCAGT 
FOXO1 Mouse ChIP CCGGAGTTTAACCAGTCCAA GTCCTCACTCTCCTCCAGCA 
ACAA2 Mouse RT-qPCR ACGCCTTGCAGTCTCAGCAG CCTCAATGGGTGCCATCTCC 
AKAP1 Mouse RT-qPCR ATGGCAATCCAGTTGCGTTC TCCACCTGCTTATCACTGCTG 
CIDEA Mouse RT-qPCR TCCCAGTCTGCAAGCAACCA GTCCTTGGGGTTCAGCCTGT 
COX7A1 Mouse RT-qPCR GGGGAATGGACAACGTCCTG AGGCCCAGCCCAAGCAGTAT 
COX8B Mouse RT-qPCR AGCCCATGTCTCTGCCAAGC TGGAACCATGAAGCCAACGA 
NDUFV1 Mouse RT-qPCR GTGCGGGTATCTGTGCGTT GGTTGGTAAAGATCCGGTCTTC 
SCP2 Mouse RT-qPCR AATGCTGCCCCACCTCAGAT CAGGCCGTACTGCTGCACAA 
DGAT1 Mouse ChIP GCGTCAACTGGAGAGTCCAT ACTGCAATTCCCAGAGTGCT 
FASN Mouse ChIP GTGCTTGGTCACACTGGAAA GGTGTCCAATTGGTTTCGAT 
mt-ND1 Mouse RT-qPCR GCCACCTTACAAATAAGCGCTCTC ACGCAATTTCCTGGCTCTGC 
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TFAM Mouse RT-qPCR CTGCACTCTGCCCATCCAAA CTGAGCATTCGCAGGCCTTT 
Table 3. Primer sequences. 
Chromatin Immunoprecipitations 
All cells were cross-linked in 1% formaldehyde then washed with ice cold 1X 
PBS containing 1X protease inhibitor cocktail. Hypotonic lysis was performed by adding 
500uL hypotonic lysis buffer ((10mM HEPES, 1.5 mM MgCl2, 10mM KCl, .5 mM DTT, 
.2mM PMSF, and 1X protease inhibitor cocktail), incubating on ice for 20 minutes and 
spun at maximum speed for 10 minutes. The supernatant was discarded. Cell pellet was 
incubated in 100uL per IP of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCL pH 8, 1X protease inhibitor cocktail) for minutes on ice then sonicated 2X 10 
minutes at maximum power in a Biorupter (Diagenode) sonicator. Debris was removed 
by centrifugation for 10 minutes at 13,000 RPM at 4C in special thin plastic tubes. The 
supernatant was diluted 10-fold in ChIP dilution buffer (.01% SDS, 1.1% Triton, 1.2 mM 
EDTA, 16.7 mM Tris-HCL pH8, 167 mM NaCl, 1X protease inhibitor cocktail). 50 uL of 
chromatin solution was set aside as input. Antibodies as described in Table was added to 
1 mL of chromatin solution and incubated overnight at 4C with rotation. 1 mL of 
chromatin solution without antibody was used for IgG control. Immune complexes were 
collected using 50 uL of Protein A agarose slurry for one hour at 4C with rotation. Beads 
were pelleted for 1 minute at 1000 RPM at 4C then washed in Centrifugal Filters 
(Millipore) for 3 minutes at 5000 RPM with 500 uL of each subsequent listed buffer: 
Low salt wash buffer (.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris-HCl pH8, 150 
mM NaCl), High salt wash buffer ((.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris-HCl 
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pH8, 500 mM NaCl), Lithium Chloride buffer (.25 M LiCl, 1% NP-40, 1% deoxycholate, 
1 mM EDTA, 10 mM Tris-Hcl pH8) and TE buffer (1 mM EDTA, 10 mM Tris-HCl 
pH8). Immune complexes were eluted by adding 300 uL of elution buffer (1% SDS, 0.1 
M NaHCO3) to pelleted beads then put on the shaker and incubated at RT for 30 minutes. 
Beads were spun down and the supernatant was keep. Cross-links were reversed at 65C 
overnight. 250 uL elution buffer was added to inputs and cross-links were reversed at 
65C overnight. DNA was recovered with phenol/chloroform extraction by adding 300 uL 
phenol:chloroform: IAA vortexed for 10 seconds, then spun at 4C at maximum speed for 
15 minutes. Supernatant was removed and 3 uL of glycogen was added and incubated for 
1 minute. 30 uL Na acetate (3M) was added and incubated for 1 minute. 750 mL of cold 
100% ethanol was added and samples were placed in -80C for 2 hours. Samples were 
spun down at maximum speed for 20 minutes, washed with 1 mL 70% ethanol and pellets 
were dried overnight at RT on the bench. DNA pellets were then resuspended in water 
and used for qPCR reactions.  
Genomic DNA isolation, mitochondria content and PCR 
To perform mouse genotyping, genomic DNA was isolated from cut tails by 
adding 1 mL 50 mM Sodium hydroxide (NaOH). This was heated for 10 minutes at 100C 
then neutralized with 80 uL 1mM Tris-HCL, pH 8. 2uL was added to the PCR reaction.  
DNA was extracted from BAT following manufacturer’s instructions of the 
BuccalAmp DNA Extraction Kit (Epicentre). DNA amplification of the mitochondrial-
encoded NADH dehydrogenase 1 (mt-ND1) relative to nuclear TFAM was used to 
determine mitochondrial DNA copy numbers using primers listed in Table 3. 
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PCR reactions were performed using Fermentas DreamTaq Green PCR Master 
Mix (Thermo Scientific) according to manufacturer’s guidelines on Veriti thermos cycler 
(ABI) machine. Reactions were run on 1.5% agarose (Bio-Rad) gels in 1X TBE buffer 
(0.9 M Tris pH 8, 28 mM Na2EDTA, 1.12 M Boric acid) containing 1X GreenGlo Safe 
DNA Dye (Denville), visualized on Chemi DocTM XRS+ imaging station (Bio-Rad) 
using Image Lab software (Bio-Rad) and products were compared to exACTGene 1kb 
DNA ladder (Fisher) ladder to determine size. 
Mitochondria isolation, content and Seahorse 
Brown Adipose Tissue was isolated from GPS2-WT and KO mouse and weighed. 
Isolated BAT was rinsed and minced in ice-cold PBS then homogenized in a glass-teflon  
dounce  homogenizer  containing  SHE pH=7.2 (250 mM Sucrose, 5mM HEPES, 2 mM 
EGTA, BSA 2%.) + BSA buffer. After 9-10 strokes through the tefflon pestle the 
homogenate was centrifuged at 900xg for 10 min at 4°C. The resulting supernatant was 
then centrifuged at 9000xg for 10 min at 4°C and the pellet was washed once and then re-
suspended in SHE without BSA. Protein content was measured by BCA assay (Bio-Rad).  
For mitochondrial activity, 4µg of mitochondrial protein fractions were loaded per 
well for complex I driven respiration (pyruvate+malate) and 2µg for complex II-driven 
respiration (succinate+rotenone) in 25 µl of Mitochondrial Assay Solution pH 7.2 (MAS: 
100mM KCl, 10mM KH2PO4, 2mM MgCl2, 5mM  HEPES,  1mM  EGTA,  0.1%  BSA  
and  1mM  GDP) per Seahorse XF96 well. The plate was centrifuged at 4°C, 5 min at 
3400 rpm. Then, 110 µl of MAS with the respective fuels were carefully added per well. 
Plate was warmed at 37°C for 4 min then oxygen consumption was measured at 37°C 
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using a Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, 
MA). Mitochondrial stress test compounds (10 µM oligomycin, 2.5 µM FCCP and 10 µM 
antimycin A) were injected through ports A, B, and C, respectively, to measure 
mitochondrial respiration linked to ATP synthesis, leak, and maximal respiratory capacity 
according to the manufacturer’s instructions. Pyruvate was used at 5mM, malate 5mM, 
succinate 5mM and rotenone 2µM. ADP was injected at port A (3.5mM), Oligomycin A 
at port B (3.5µM), FCCP at port C (4µM) and Antimycin A at port D (4µM). 
Isolation of B cells 
Bone marrow cells were flushed from femoral bone by flush, peritoneal cavity 
cells were isolated by lavage of the peritoneal cavity and splenic B cells were isolated 
from single cells suspension of total splenocytes prepared according to standard protocols 
118. B cell purification was achieved by magnetic depletion using the MACS Pan B cells 
Isolation Kit (Miltenyi Biotech). Purity of the B cells populations was verified by flow 
cytometric analysis with CD19, CD11b and CD3 labeling. 
FACS analysis 
SVF cells were purified as described above. Flow cytometry analyses were 
performed using the following anti-mouse antibodies: PerCP anti CD11b (Biolegend), 
FITC antiF4/80 (BioRAD); Single cell suspensions were stained with Aqua Zombie dye, 
washed, pre-blocked with mouse FcBlock (Biolegend), and stained with antibody 
cocktails in the presence of Brilliant Violet buffer (BD Biosciences). Ultracomp beads 
(eBioscience) stained with abovementioned antibodies and ArC beads (Life 
Technologies) stained with Aqua Zombie dye were used for compensation in 
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FACSDIVA. All data were acquired on a SORP LSRII (BD Biosciences). At least 20,000 
events were collected from each sample. All manual analysis was performed by a blinded 
investigator using FlowJo 10. Results presented are from three independent experiments, 
with statistical significance calculated by two-tailed Student’s t test.  
.
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CHAPTER THREE – SYSTEMIC INSULIN SENSITIVITY IS REGULATED BY 
GPS2 THROUGH INHIBITION OF AKT UBIQUITINATION AND 
ACTIVATION IN ADIPOSE TISSUE 
This chapter is adapted from: Cederquist, C.T. et al. (2017). Systemic insulin sensitivity 
is regulated by GPS2 inhibition of AKT ubiquitination and activation in adipose tissue. 
Mol Metab. 6, 125-137. 86 
This chapter is also adapted from: Lentucci, C., Belkina, A.*, Cederquist, C.T.*, et al. 
(2017). Inhibition of Ubc13-mediated ubiquitination by GPS2 regulates multiple stages 
of B cell development. J Biol Chem, online Dec 30. 85 
*= These authors contributed equally to this work.  
Abstract 
 Insulin signaling plays a unique role in the regulation of energy homeostasis and 
the impairment of insulin action is associated with altered lipid metabolism, obesity, and 
Type 2 Diabetes. The main aim of this study was to provide further insight into the 
regulatory mechanisms governing the insulin signaling pathway by investigating the role 
of non-proteolytic ubiquitination in insulin-mediated activation of AKT. The molecular 
mechanism of AKT regulation through ubiquitination is first dissected in vitro in 3T3-L1 
preadipocytes and then validated in vivo using mice with adipo-specific deletion of 
GPS2, an endogenous inhibitor of Ubc13 activity (GPS2-AKO mice). Our results 
indicate that K63 ubiquitination is a critical component of AKT activation in the insulin 
signaling pathway and that counter-regulation of this step occurs by GPS2 preventing 
AKT ubiquitination through inhibition of Ubc13 enzymatic activity. Removal of this 
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negative checkpoint, through GPS2 downregulation or genetic deletion, results in 
sustained activation of insulin signaling both in vitro and in vivo. As a result, the balance 
between lipid accumulation and utilization is shifted toward storage in the adipose tissue 
and GPS2-AKO mice become obese under a normal laboratory chow diet. However, the 
adipose tissue of GPS2-AKO mice is not inflamed, the levels of circulating adiponectin 
are elevated and systemic insulin sensitivity is overall improved. My findings 
characterize a novel layer of regulation of the insulin signaling pathway based on non-
proteolytic ubiquitination of AKT and define GPS2 as a previously unrecognized 
component of the insulin signaling cascade. In accordance with this role, we have shown 
that GPS2 presence in the adipocytes modulates systemic metabolism by restricting the 
activation of insulin signaling during the fasted state, whereas in absence of GPS2, the 
adipose tissue is more efficient at storing lipids and obesity becomes uncoupled from 
inflammation and insulin resistance. 
Introduction 
 The adipose tissue is an extremely flexible organ that plays a critical role in the 
regulation of energy homeostasis through both triglyceride storage and adipokine 
secretion 9,119. The health of the white adipose tissue, and thus of the whole body, largely 
depends on the existence of a proper balance between lipid storage and utilization, which 
is challenged under conditions of excess food intake. Major pathological consequences of 
overnutrition and obesity result from an increase in lipid flux to non-adipose organs and 
the development of insulin resistance 57,120. During the normal cycles of daily fasting and 
feeding, adipose tissue metabolism is tightly regulated to respond to the energetic 
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demands of the organism. Insulin signaling plays a key role in this process by promoting 
nutrient storage during the fed state via enhanced glucose uptake and triglyceride 
synthesis, and by inhibiting triglyceride breakdown and fatty acid release through 
lipolysis 121,122. The AKT/PKB kinase is an obligatory mediator of the insulin signaling 
pathway downstream of phosphatidylinositol 3-kinase (PI3K) 24,123. Full AKT activation 
is promoted by dual phosphorylation by PDK1, a PI3K-dependent kinase, and the 
mTOR-rictor complex. The key rate-limiting event for AKT activation is not the 
phosphorylation per se, but rather its translocation to the plasma membrane. Accordingly, 
full signaling capacity is achieved by tethering AKT to the plasma membrane 124-127. 
Intriguingly, recent evidence indicates that AKT recruitment to the membrane, and thus 
activation, upon stimulation with the growth factors EGF and IGF is unexpectedly 
regulated through K63 ubiquitination 36,40,128. However, it is currently unknown whether 
AKT ubiquitination similarly contributes to the regulation of metabolic homeostasis 
through modulation of insulin signaling. 
Ubiquitination is a reversible modification that is achieved via the sequential 
actions of several classes of enzymes, including an ubiquitin (Ub)-activating enzyme 
(E1), an Ub-conjugating enzyme (E2), and an Ub ligase (E3) 129,130.  Poly-ubiquitination 
of target proteins with chains of different topology can promote either protein 
degradation or serve, as in the case of other post-translational modifications, to influence 
protein function  and interactions 73,131.  The key E2 enzyme for promoting the formation 
of non-proteolytic, K63 ubiquitin chains is Ubc13, which catalyzes the synthesis of 
ubiquitin chains in complex with the non-catalytic subunits Mms2/Uev1A and specific 
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E3 ligases 132-134. Consistent with the flexibility of ubiquitination as a tight regulatory 
switch for signaling pathways is the existence of multiple strategies to rapidly reverse the 
active mark. Among them, best characterized is the removal of ubiquitin modifications by 
chain specific deubiquitinases 129,135-137, as reported in the case of AKT deubiquitination 
by CYLD 42,138. However, an equally, if not more effective strategy is restricting the 
deposition of the ubiquitin chains through inhibition of the ubiquitination machinery. 
Examples of inhibitors behaving in this manner are the ubiquitin thioesterase OTUB1 in 
the DNA damage response pathway and G-protein Pathway Suppressor 2 (GPS2) in the 
TNFR1 signaling pathway 84,139. 
GPS2 is a small multifunctional protein that was originally identified while 
screening for suppressors of Ras activation in the yeast pheromone response pathway 81. 
Recent studies by our lab and others indicate that GPS2 plays an important anti-
inflammatory role in adipose tissue and macrophages and is required for the expression 
of genes regulating cholesterol and triglyceride metabolism 79,84,89,91,97.  Due to multiple 
functional interactions existing between GPS2 and various transcriptional regulators, 
GPS2 activity has been mainly studied in the context of its nuclear functions, including 
both transcriptional repression and activation 79,84,87-90,92,93,95,97,98,105. However, GPS2 also 
plays an important non-transcriptional role in the cytosol by regulating JNK activation 
downstream of TNFR1 84. Intriguingly, our findings reveal that GPS2 activity in different 
cellular compartments relies on a conserved regulatory strategy based on the inhibition of 
ubiquitin conjugating complexes that are responsible for the formation of K63 ubiquitin 
chains (TRAF2/Ubc13 in the cytosol and RNF8/Ubc13 in the nucleus) 79,84. Furthermore, 
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recent data indicate that GPS2 directly inhibits Ubc13 enzymatic activity85, suggesting 
that GPS2-mediated regulation might extend to other signaling pathways relying on 
Ubc13-mediated ubiquitination events. Here, we have investigated the hypothesis that 
GPS2 is required for restricting the activation of the insulin signaling pathway through 
inhibition of Ubc13-mediated ubiquitination of AKT. 
Results 
AKT activation in the insulin signaling cascade is regulated by ubiquitination 
 Non-proteolytic ubiquitination of AKT has been recently described as a key step 
in the activation cascades downstream of EGF and IGF receptor stimulation 40,41. Despite 
some differences in the enzymatic machineries that are enlisted in the two different 
pathways, in both cases, K63 ubiquitination plays a critical role in promoting AKT 
recruitment to the plasma membrane 40,41. Membrane recruitment of AKT through 
anchoring to phosphoinositol-3,4,5-triphosphate (PIP3) is also a limiting step in the 
insulin signaling pathway 35,140. However, it is currently unknown whether ubiquitination 
is required for the activation of AKT upon insulin stimulation. To address this question, 
we first asked whether AKT is post-translationally modified by the addition of K63 
ubiquitin chains upon insulin stimulation of 3T3-L1 preadipocytes.  As shown in Figure 
3.1A, we observed that AKT undergoes K63 ubiquitination within minutes of insulin 
stimulation. The peak of ubiquitination slightly precedes AKT maximal phosphorylation 
by the phosphoinositide-dependent protein kinase 1 (PDK1) (Figure 3.1A), in accord 
with the proposed function. Next, we addressed whether ubiquitination occurs on the 
same sites described in the context of EGF/IGF signaling 40, and whether this  
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Figure 3.1 – AKT K63 ubiquitination and activation is regulated by the ubiquitin 
conjugating enzyme Ubc13. 
(A) Detection of K63 ubiquitination by IP/WB of AKT in 3T3-L1 preadipocytes serum 
starved overnight prior to stimulation with 100 nM insulin. Phosphorylation of AKT on 
Thr308 is measured in parallel on whole cell extracts from the same cells and normalized 
to total AKT levels. (B) Inducible AKT1 and AKT2 deletion upon 4-hydroxy tamoxifen 
treatment (4OH- Tam) is rescued by transient overexpression of AKT2 WT or 
ubiquitination mutants. Protein expression levels and insulin mediated activation of 
AKT2 and downstream effectors PRAS40 and ribosomal protein S6 are assayed by WB 
in whole cell extracts. (C) WB analysis of phospho-AKT/total AKT on whole cell 
extracts from siCTRL versus siUBC13 transiently transfected 3T3-L1 preadipocytes. 
Cells were stimulated with insulin (5’) after overnight serum starvation. All western blots 
are representative images of at least three independent experiments.  
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modification is required for activation of the insulin pathway. To answer these questions, 
we reconstituted AKT1/2/3 null cells, generated from primary brown adipocyte 
precursors, with either wild type HA-AKT2 or HA-AKT2 mutants in which we had 
disrupted either Lys8 (AKT2-K8R), Lys14 (AKT2-K14R), or both (AKT2-K8R/K14R) 
by targeted mutagenesis. Their overexpression in AKT null cells revealed that the single 
mutants were still partially phosphorylated upon insulin stimulation, whereas removal of 
both ubiquitination sites resulted in a complete loss of AKT phosphorylation (Figure 
3.1B). The activation of downstream AKT targets, such as PRAS40 and ribosomal 
protein S6, was also inhibited in cells reconstituted with the double mutant (Figure 
3.1B). Together, these results indicate that AKT ubiquitination is a required step for full 
activation of the insulin pathway. To further confirm this conclusion and explore which 
ubiquitination machinery mediates AKT ubiquitination within the insulin pathway, we 
downregulated the E2 conjugating enzyme Ubc13 responsible for the synthesis of K63 
ubiquitin chains by transient siRNA transfection. Ubc13, in concert with specific E3 
ligases, was previously found responsible for mediating the ubiquitination, and thus 
activation, of AKT upon stimulation of IGF, EGF and ErbB receptors 40,41,141. In accord 
with these results, we observed that basal activation of AKT, albeit already very low, is 
reduced upon Ubc13 downregulation. In addition, our results indicate that disrupting 
AKT ubiquitination through downregulation of Ubc13 significantly impaired insulin-
dependent phosphorylation of AKT (Figure 3.1C Figure 3.3A). Together our data 
indicate that AKT is K63 ubiquitinated upon insulin stimulation and that Ubc13-mediated 
K63 ubiquitination is required for full activation of AKT and its downstream targets,  
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Figure 3.2 – AKT K63 ubiquitination and activation is regulated by GPS2, the 
negative regulator of the ubiquitin conjugating enzyme Ubc13. 
(A) WB analysis of phospho-AKT/total AKT and phospho- GSK3B/total GSK3B in 
cytosolic cell extracts from proliferating 3T3-L1 preadipocytes transiently transfected 
with siCTRL (WT) or siGPS2 (GPS2-KD). (B) WB analysis of phospho-AKT/total AKT 
in whole cell extracts from 293T cells. (C) WB analysis of phospho-AKT/total AKT in 
whole cell extracts from WT and GPS2-KD 3T3-L1 preadipocytes starved overnight 
prior to insulin stimulation (3’). All western blots are representative images of at least 
three independent experiments.  
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hence raising the interesting question of whether AKT ubiquitination can be modulated to 
regulate insulin signaling.   
Previous studies from our lab show that GPS2 negatively regulates different 
cellular functions through inhibition of K63 ubiquitination events 79,84. Recent work has 
revealed that this effect is achieved through direct inhibition of Ubc13 enzymatic  
activity72. Because our data indicate that Ubc13-mediated ubiquitination is required for 
AKT phosphorylation and activation, we then asked whether GPS2 negatively regulated 
the activation of the insulin pathway. To investigate this hypothesis, we monitored AKT 
activation in 3T3-L1 preadipocytes upon modulation of GPS2 expression. First, we 
downregulated GPS2 by transient siRNA transfection in 3T3-L1 preadipocytes (GPS2-
KD) (Figure 3.3B). A significant increase in the basal level of AKT phosphorylation was 
observed upon GPS2 downregulation (Figure 3.2A), indicating that GPS2 is required for 
restricting the constitutive activation of AKT in proliferating cells under basal conditions. 
Similar results were observed in human 293T cells (Figure 3.2B), suggesting that GPS2-
mediated regulation of AKT is conserved among different cell types. Next, to specifically 
investigate the relevance of GPS2-mediated inhibition in the context of insulin signaling, 
we starved GPS2 KD cells and subjected them to insulin stimulation. Again, AKT 
activation was enhanced in GPS2-KD cells (Figure 3.2C).  
Together, these results reveal that Ubc13-mediated K63 ubiquitination of AKT 
represents a novel, key regulatory node of the insulin signaling pathway. GPS2, by virtue 
of its ability to inhibit Ubc13 enzymatic activity, emerges as a novel regulator of the  
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Figure 3.3 – Efficient knockdown of Ubc13 and GPS2 is achieved in cell lines. 
(A) siRNA validation by RT-qPCR of transiently transfected 3t3-L1 cells comparing 
siCTRL versus siUBC13 treated cells. Results are expressed as mean-/+SEM from 3 
independent experiments and statistical significance was calculated comparing the 3 
independent experiments. (B) siRNA validation by RT-qPCR of transiently transfected 
3t3-L1 cells comparing siCTRL versus siGPS2 treated cells. Results are expressed as 
mean-/+SEM from 3 independent experiments and statistical significance was calculated 
comparing the 3 independent experiments. Statistical significance was calculated by two-
tailed Student’s t test; * represents p value <0.05 and ** p value < 0.01. 
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insulin pathway required for restricting the activation of AKT and downstream effectors 
both in presence and absence of stimulation. 
Constitutive AKT ubiquitination and activation in GPS2-deficient adipocytes 
Properly functioning insulin signaling is especially important in adipocytes to 
maintain cell homeostasis, and allow for appropriate responses to metabolic cues. Based  
on our findings of GPS2 acting as a negative regulator of AKT activation, we 
hypothesized that GPS2 would play an important physiologic role in adipose tissue. To 
investigate the physiologic relevance of GPS2 in regulating insulin signaling in the 
adipose tissue, we generated an adipo-specific knockout mouse model (GPS2-AKO) by 
crossing GPS2fl/fl mice, carrying LoxP sites flanking exons 3-6, with Adipo-Cre mice 
(Jackson laboratories) 113. The efficiency of this deletion strategy was confirmed by 
genomic PCR, western blotting and gene expression analysis (Figure 3.4A-D). Together, 
these experiments confirmed that GPS2 deletion is specific to mature adipocytes within 
the adipose tissue. Then, we investigated in in vitro differentiated adipocytes from the 
stromal vascular fraction (SVF) of either wild type (WT) or mutant (GPS2-AKO) mice 
the hypothesis that loss of GPS2 results in increased ubiquitination and activation of 
AKT. The efficiency of differentiation was similar for cells of both genotype (Figure 
3.5). However, when assaying the level of AKT ubiquitination by IP/WB using an 
antibody specific against K63 ubiquitin chains for detection, we found a striking increase 
in AKT-associated ubiquitin chains in GPS2-deficient adipocytes compared to their 
wildtype littermates (Figure 3.6A). The increase in ubiquitination was associated with 
enhanced basal phosphorylation on both Ser473 and Thr308 both in absence of  
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Figure 3.4 – Adipocyte-specific GPS2 Knockout mice show specific deletion for 
GPS2 only in adipose tissue. 
(A) Confirmation of GPS2 deletion in the adipose tissue of GPS2-AKO mice by genomic 
DNA analysis. (B) RT-qPCR analysis of GPS2 mRNA expression in white epididymal 
(EPI), subcutaneous (SC), and brown (BAT) adipose tissue depots and liver (LIV) from 
AKO versus WT mice, n=6-7. (C) GPS2 mRNA expression in primary adipocytes 
isolated from white fat depots, n=3-4. (D) Confirmation of protein knockout by WB in 
extracts from WAT, BAT, and LIV tissues. Results are expressed as mean -/+SEM. 
Statistical significance was calculated by two-tailed Student’s t test; * represents p value 
< 0.05 and **p value < 0.01. All western blots are representative images of at least three 
independent experiments.  
 
  
		
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 – No differences are observed in differentiation capacity in WT vs GPS2-
AKO. 
RT-qPCR analysis of gene markers of adipogenesis in in vitro differentiated adipocytes 
from WT versus AKO mice at specified time points. Results are expressed as mean -
/+SEM. Statistical significance was calculated by two-tailed Student’s t test; * represents 
p value <0.05 and ** p value < 0.01. 
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Figure 3.6 – In vitro differentiated adipocytes from GPS2-AKO mice display 
hyperubiquitination and increased phosphorylation of AKT. 
(A) IP/WB analysis of AKT ubiquitination with K63 ubiquitin chains in in vitro 
differentiated adipocytes from AKO versus WT mice. (B) WB analysis of phospho-AKT/ 
AKT in whole cell extracts from in vitro differentiated adipocytes upon insulin 
stimulation (3’) after overnight serum starvation. All western blots are representative 
images of at least three independent experiments.  
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stimulation and upon short-term insulin treatment (Figure 3.6B), confirming that AKT 
ubiquitination and activation are strongly enhanced in cultured adipocytes depleted of 
GPS2.  
Next, we confirmed that insulin-dependent stimulation of AKT is affected by 
GPS2 deletion in vivo by monitoring AKT activation in adipose tissue under fasted and 
insulin stimulated conditions. Strikingly, we observed a significant increase in basal 
phosphorylation of AKT in both the whole subcutaneous adipose tissue depot and in 
mature adipocytes isolated from the epididymal adipose tissue depot of GPS2-AKO mice 
following overnight fasting (Figure 3.7A). In the same conditions, removal of GPS2-
mediated inhibition of Ubc13 activity in adipocytes also led to increased activation of 
JNK (Figure 3.7B), as expected based on previous findings 84,93. In addition, we 
observed a significant increase in the level of AKT phosphorylation and activation in the 
subcutaneous adipose tissue when mice were injected with insulin for a short time prior 
to sacrifice (Figure 3.7C). Enhanced activation of insulin signaling pathways 
downstream of AKT in the adipose tissue from GPS2-AKO mice was confirmed by 
augmented phosphorylation of AKT target substrate GSK3b (Figure 3.7C). Therefore, 
our results together indicate that GPS2 deletion promotes sustained basal and insulin-
stimulated phosphorylation and activation of AKT, and downstream effectors of the 
insulin signaling pathway, in vivo in the adipose tissue. 
		
75 
Altered regulation of lipolysis and lipogenesis in GPS2-AKO mice cause adipocyte 
hypertrophy and excessive body adiposity  
A tight regulation of insulin action in adipose tissue is required for the proper 
modulation of nutrient storage and mobilization throughout the daily cycles of fasting and 
feeding 24,142,143. Our in vitro and in vivo results combined suggest that removal of GPS2-
mediated regulation is sufficient to promote aberrant activation of the insulin signaling 
pathway through constitutive phosphorylation and activation of AKT. Thus, we asked 
whether the fat-specific deletion of GPS2 affects nutrient storage, lipid fluxes and whole 
body metabolism in vivo. First, we observed that GPS2-AKO mice were healthy and 
fertile, but could be easily distinguished from their wild type (WT) littermates based on 
their larger size (Figure 3.8A). The difference in body weight was not apparent at birth 
but increased gradually with time (Figure 3.8B) and became significant once mice 
reached adulthood (Figure 3.8C). Echo-MRI scans of these mice confirmed that the 
increase in body mass was attributed to an increase in fat mass, without significant 
changes in lean mass (Figure 3.9A). Gross appearance revealed that all adipose tissue 
depots appeared larger when comparing GPS2-AKO to WT littermates (Figure 3.9B). 
Weights of individual white fat depots were significantly higher for GPS2-AKO mice 
(Figure 3.9C). The interscapular brown adipose tissue (BAT) also tended to be larger 
(Figure 3.9C). And, the enhanced adiposity correlated with a substantial increase in the 
size of adipocytes (hypertrophy) within both the SC and EPI depots (Figure 3.9D). In 
conclusion, these data indicate that GPS2-depleted adipocytes expand more than their  
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Figure 3.7 – Primary adipocytes and adipose tissue from GPS2-AKO mice show 
increased phosphorylation of AKT under various conditions and increased 
phosphorylation of JNK is observed in GPS2-AKO adipocytes. 
(A) WB analysis of phospho-AKT/total AKT on whole cell extracts from WAT tissue 
and primary adipocytes isolated from the EPI tissue after overnight fast. (B) WB analysis 
of phospho-JNK/total JNK on whole cell extracts from primary adipocytes. (C) WB 
analysis of phospho-AKT/total AKT and phospho-GSK3B/total GSK3B in whole cell 
extracts from WAT after i.p. insulin injection (0.5 U/kg body weight). All western blots 
are representative images of at least three independent experiments.  
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Figure 3.8 – GPS2-AKO mice have increased total body weight compared to WT 
mice. 
(A) Representative image of whole body morphology of adult WT and GPS2-AKO mice. 
(B) Progressive body weight gain in AKO versus WT mice, WT n=5-9, KO n=7-11. (C) 
Total body weight of 4-6 months old mice, n=5. Results are expressed as mean -/+SEM. 
Statistical significance was calculated by two-tailed Student’s t test; *represents p value < 
0.05 and **p value < 0.01.  
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wild type counterparts, resulting in elevated adipose tissue mass and larger body weight, 
even when mice are fed a normal chow diet.  
Adipocytes are the primary site of energy storage.  The balance between lipid 
storage in the form of triglycerides and mobilization as released free fatty acids is directly 
regulated by insulin through AKT-dependent as well as AKT-independent pathways 
57,144,145 In this context, a major physiological function of insulin in the postprandial, 
anabolic state is to support the accumulation of lipid storage by promoting de novo 
lipogenesis while restraining lipid mobilization via lipolysis. Based on the enhanced AKT 
activation we observed in the adipose tissue of both fasted and insulin-stimulated GPS2-
AKO mice, we asked whether an impairment of the regulated cycles of lipogenesis and 
lipolysis was underlying the increased adipocyte cell size and body adiposity of these 
mice.  
Our previous work showed that GPS2 overexpression in aP2-GPS2 transgenic 
mice promoted a strong increase in the phosphorylation, and thus activation, of hormone 
sensitive lipase, HSL 79. Here, we found that GPS2 deletion promoted the opposite 
phenotype. In isolated adipocytes from fasted GPS2-AKO mice, HSL phosphorylation 
was completely blunted in contrast to the strong signal observed in adipocytes from WT 
littermates (Figure 3.10A). Similar results were observed upon isoproterenol stimulation 
of in vitro differentiated adipocytes from WT or GPS2-AKO mice, with the induced HSL 
phosphorylation being severely reduced in absence of GPS2 (Figure 3.10B). In 
agreement with GPS2 being required for the priming of HSL and ATGL promoters only 
during the early stages of adipocyte differentiation prior to the expression of  
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Figure 3.9 – Increased fat mass and adipocyte cell size is observed in GPS2-AKO 
mice.  
(A) Body composition analysis of total fat versus lean mass measured by EchoMRI 
scanning of WT and AKO mice at 4-6 months old, n=5. (B) Representative images of 
gross appearance of EPI, SC, and BAT depots in AKO versus WT mice at 4-6 months 
old. (C) Individual adipose tissue depot and liver weights in AKO versus WT mice at 4-6 
months old, n =9-11. (D) Representative H&E staining of paraffin-embedded EPI and SC 
sections imaged at 10X magnification. Results are expressed as mean -/+SEM. Statistical 
significance was calculated by two-tailed Student’s t test; *represents p value < 0.05 and 
**p value < 0.01.  
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Figure 3.10 – Adipocytes from GPS2-AKO mice have impaired phosphorylation of 
HSL, as a marker of lipolysis, despite trends of increased ATGL and HSL. 
(A) WB analysis of phospho-HSL/total HSL in whole cell extracts of primary adipocytes 
isolated from the EPI adipose tissue depot of AKO versus WT mice after overnight 
fasting. (B) WB analysis of phospho-HSL/total HSL protein levels in whole cell extracts 
from in vitro differentiated adipocytes in fasted or isoproterenol (10 uM) stimulated 
conditions. (C) RT-qPCR analysis of ATGL and HSL, lipolysis markers, in WAT of 
AKO versus WT mice, n= 4-5. Results are expressed as mean-/+SEM. (C) Western blot 
analysis of ATGL and HSL normalized to b-tubulin in whole cell extracts from WAT 
from AKO versus WT mice in fasting conditions. Statistical significance was calculated 
by two-tailed Student’s t test; * represents p value <0.05 and ** p value < 0.01. All 
western blots are representative images of at least three independent experiments.  
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adiponectin79, we did not observe any significant change in the expression of HSL upon 
GPS2 deletion in adiponectin-expressing, mature adipocytes. However, we unexpectedly 
observed a trend for increased ATGL mRNA and protein levels, which could reflect an 
attempt at compensating for the reduced lipolysis (Figure 3.10B-D). Upstream regulation 
of the lipolysis pathway was also impaired as shown by reduced phosphorylation of PKA 
and PKA substrates in subcutaneous white adipose tissue homogenates (Figure 3.11A). 
To further confirm that lipid mobilization from the adipose tissue is impaired in GPS2-
AKO mice, we confirmed that lipolysis is impaired in absence of GPS2 ex vivo and in 
vivo.  Ex vivo, the rate of lipolysis, as assessed by measuring glycerol release from in 
vitro differentiated adipocytes, was severely reduced in GPS2-deficient cells compared to 
wild type counterparts (Figure 3.11B). In vivo, GPS2-AKO mice lost significantly less 
body weight after an overnight fast than their WT littermates, in accordance with their 
impaired ability to promote lipid release from triglyceride stores (Figure 3.11C). Thus, 
our current and previous work combined indicates that GPS2 is indeed required for lipid 
mobilization through lipolysis. Interestingly, it appears that GPS2 plays complementary 
genomic and non-genomic roles in regulating different steps of the lipolysis pathway in 
differentiating pre-adipocytes and mature adipocytes.  
Next, we investigated the effect of enhanced insulin signaling on the regulation of 
lipogenesis.  In both adipose tissue and liver, acute stimulation of de novo lipogenesis 
(DNL) is mainly regulated by insulin and glucose availability through the transcriptional 
activities of SREBP1, ChREBP and LXRs 121,146,147. Gene expression analysis by RT-
qPCR showed a significant increase in the mRNA levels of  
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Figure 3.11 – Improved lipid storage in the white adipose tissue of GPS2-AKO mice 
is a result of impaired lipolysis. 
(A) WB analysis for markers of active lipolysis in whole cell extracts from the WAT of 
fasted mice. (B) Basal and isoproterenol induced lipolysis assay on in vitro differentiated 
adipocytes. Statistical significance was calculated comparing 3 independent experiments. 
(C) Percentage of total body weight loss after prolonged overnight fast, n = 7. Results are 
expressed as mean -/+SEM. Statistical significance was calculated by two-tailed 
Student’s t test; *represents p value < 0.05 and **p value < 0.01. All western blots are 
representative images of at least three independent experiments.  
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Figure 3.12 – Improved lipid storage capacity in GPS2-AKO mice is a result of 
increased lipogenesis. 
(A) qPCR analysis of lipogenic markers in WAT of AKO versus WT mice, n =5-7. (B) 
WB analysis of phospho-ACC/total ACC and phospho-AMPK/total AMPK in whole cell 
extracts from the WAT of fasted mice. Results are expressed as mean -/+SEM. Statistical 
significance was calculated by two-tailed Student’s t test; *represents p value < 0.05 and 
**p value < 0.01. All western blots are representative images of at least three independent 
experiments.  
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the lipogenic genes Fasn, Dgat1, Dgat2, AGPAT2 and Acaca in the subcutaneous WAT 
of GPS2-AKO mice compared to WT littermates (Figure 3.12A). In addition to the 
transcriptional regulation of enzyme availability, insulin-mediated activation of AKT 
impinges upon DNL through AMPK inhibition, resulting in dephosphorylation and 
activation of the Acetyl-CoA carboxylase (ACC) 148. In agreement with AKT being 
constitutively activated in GPS2-AKO mice, we observed both a significant decrease in 
active AMPK and decreased phosphorylation of ACC in the white adipose tissue of 
GPS2-AKO mice (Figure 3.12B). Together, these results are consistent with the 
hypothesis that both in the fed and fasted state lipogenesis is enhanced while lipid 
mobilization is impaired in GPS2-AKO mice, markedly shifting the balance toward fat 
storage.  
Fat-specific deletion of GPS2 results in improved systemic insulin sensitivity 
Sustained insulin signaling, improved lipid storing capacity of the adipose tissue, 
impaired adipose tissue lipolysis and enhanced DNL have all been associated with 
improved systemic insulin sensitivity 142,149-152, suggesting that adipo-specific GPS2 
deletion might be beneficial for the organism. However, obesity is generally associated 
with chronic inflammation and with the development of insulin resistance 50,153,154. To 
investigate how the removal of GPS2 and the corresponding enhanced insulin signaling 
in the adipose tissue affect the maintenance of systemic homeostasis, we first assessed the 
level of local inflammation in the adipose tissue by RT-qPCR and FACS analysis. 
Surprisingly, given GPS2 previously reported anti-inflammatory role and the obesity that 
characterize GPS2-AKO mice, no significant differences were observed in either the  
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Figure 3.13 – GPS2-AKO mice do not display adipose tissue inflammation despite 
their obesity. 
(A) RT-qPCR analysis of pro-inflammatory genes and macrophage markers in the WAT. 
Results are expressed as mean -/+ SEM. Statistical significance was calculated by two-
tailed Student’s t test; *represents p value < 0.05 and **p value < 0.01. (B) Macrophage 
infiltration in the WAT as measured by FACS analysis with quantification of f4/80 and 
CD11b positive cells. FACS statistical significance was calculated comparing 3 
independent experiments.  
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expression of gene markers of inflammation or in the amount of macrophages present 
within the adipose tissue (Figures 3.13A-B).  
Next, we sampled plasma from fasted WT and GPS2-AKO littermates for the 
presence of secreted adipokines. Plasma levels of the anti-inflammatory and insulin-
sensitizing hormone adiponectin 155,156 were found significantly elevated in GPS2-AKO 
mice despite the reported increase in body adiposity (Figure 3.14A), whereas no 
significant differences were observed in the amount of circulating leptin (Figure 3.14A).  
Consistent with an increase in circulating adiponectin and with adiponectin playing an 
important role in promoting the “healthy expansion” of the adipose tissue 157,158, we did 
not observe any evidence of hepatic steatosis in the liver of GPS2-AKO mice despite 
their increase in total body fat (Figure 3.14B). Accordingly, the expression of both 
ChREBP and SREBP1c, key markers of DNL, were found downregulated in the liver of 
GPS2-AKO mice (Figure 3.14C). The expression of key gluconeogenic enzymes, such 
as G6Pase, FBP1 and PEPCK was also reduced in the liver of GPS2-deficient mice 
(Figure 3.14C). Furthermore, we sampled circulating free fatty acids (FFA) from GPS2-
AKO and WT littermates and found a slight trend to decrease but no significant 
differences. While this result could initially appear surprising in face of the decreased 
lipolysis, it has to be taken in consideration that in a context of increased obesity 
circulating FFA are usually elevated, thus maintenance of the baseline level actually 
reflects a decrease compared to the expected phenotype (Figure 3.14D). In conclusion, 
these results indicate that despite the increase in adiposity, which typically correlates with 
metabolic dysfunction and peripheral tissue lipid deposition, GPS2 deletion in the  
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Figure 3.14 – GPS2-AKO mice have improved adipokine and circulating markers 
and improved liver function. 
(A) Plasma adiponectin and leptin levels after an overnight fast, n =7. (B) Representative 
H&E staining of paraffin- embedded liver sections imaged at 10X magnification. (C) 
Hepatic expression of gluconeogenic and de novo lipogenesis genes by RT-qPCR 
analysis. (D) Plasma non esterified free fatty acid levels in AKO versus WT mice after 
overnight fast, n=3. Results are expressed as mean -/+ SEM. Statistical significance was 
calculated by two-tailed Student’s t test; *represents p value < 0.05 and **p value < 0.01.  
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adipose tissue appears to have a positive effect on whole body lipid metabolism with 
reduced spillover to non-adipose tissues such as the liver.  
Improved lipid storing capacity of the adipose tissue can contribute to improved 
systemic insulin sensitivity 57,120,149,150. Blood glucose levels after overnight food 
deprivation were comparable between WT and GPS2-AKO matched littermate mice 
(Figure 3.15A), and glucose tolerance tests (GTT) were also normal (Figure 3.15B). 
However, plasma insulin levels under the same experimental fasting conditions were 
significantly reduced in GPS2-AKO mice (Figure 3.15C), consistent with our previous 
data that AKT is activated in vitro in basal conditions and in vivo under food deprivation  
upon GPS2 deletion/downregulation. To directly test the insulin sensitivity of GPS2-
AKO mice, we injected matching cohorts of WT and GPS2-AKO littermates with a 
suboptimal dose of insulin after a short morning fast. Baseline insulin levels of GPS2-
AKO mice trended to be lower under these experimental conditions as well (Figure 
3.15D), and insulin-induced glucose clearance was greater in GPS2-AKO mice than WT 
littermates (Figure 3.15E), confirming the predicted improvement in insulin sensitivity. 
In conclusion, our results together indicate that enhancing insulin signaling in the adipose 
tissue, through GPS2 deletion and modulation of AKT ubiquitination status, has a 
positive effect on whole body insulin sensitivity despite the increased adiposity. 
GPS2 regulation of AKT is conserved in other cell types 
While investigating the role of GPS2 in B cells using CD19-cre driven B-cell 
specific GPS2 knockout mice, results reveal that the development of BKO cells is 
impaired at the pre-BCR stage of the B cell maturation process in the bone marrow.  
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Figure 3.15 – GPS2-AKO mice have improved systemic insulin sensitivity. 
(A) Fasting blood glucose levels in AKO versus WT mice after overnight fast, n =8. (B) 
Glucose tolerance test following glucose i.p. injection (1.5 mg/g of body weight) after an 
overnight fast, n =4. (C) Plasma insulin levels in AKO versus WT mice after overnight 
fast, n =5-7. Statistical significance was calculated comparing 3 independent 
experiments. (D) Plasma insulin levels in AKO versus WT mice after a 6 hour fast, n=3-
6. (E) Insulin tolerance test after a 0.5 U/kg body weight insulin i.p. injection in AKO 
versus WT mice following a 4 h fast, n =7-8. Results are expressed as mean -/+ SEM. 
Statistical significance was calculated by two-tailed Student’s t test; *represents p value < 
0.05 and **p value < 0.01.  
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Interestingly, a similar phenotype is promoted by the deletion of FOXO1 in pre-
B/immature cells. CD19-cre driven deletion of FOXO1 is associated with a later 
impairment at the pre-B cell stage, defective light chains rearrangement and a lower 
number of recirculating mature cells159. Among genes found significantly altered in 
splenic GPS2-BKO cells were the pre-BCR adaptor protein BLNK/SLP-65, the MAPK-
activated kinase MK5 and the recombination activating gene RAG, all known to play key 
roles in FOXO1-mediated regulation of the rearrangement of immunoglobulin chains160. 
These data, along with our results showing that GPS2 can regulate AKT 
activation in adipocytes, prompted us to investigate the possibility that lack of GPS2 in B 
cells affects the early stages of B cell differentiation through increased AKT activation 
and defective transcriptional regulation of key FOXO1 target genes. We first confirmed 
GPS2 knockout efficiency in bone marrow B cells by RT-qPCR analysis was comparable 
to GPS2-BKO plenic B cells (Figure 3.16A). As previously described that GPS2 deletion 
in adipocytes leads to constitutive AKT activation, we asked whether GPS2-mediated 
regulation of AKT is conserved in B cells. Indeed, as shown in Figure 3.16B, AKT 
phosphorylation was found increased in GPS2-BKO B cells. As expected in the presence 
of enhanced AKT activation, we observed a striking upregulation of FOXO1 
phosphorylation (Figure 3.16B). It is well known that FOXO factors are negatively 
regulated by the PI3K/AKT pathway via phosphorylation and nuclear exclusion in order 
to regulate FOXO1-target gene expression160. Consistent with the increased FOXO1 
phosphorylation, we observed a significant decrease in the expression of FOXO1 target 
genes RAG1, RAG2 and BLNK (Figure 3.16C). To investigate the nuclear exclusion of  
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Figure 3.16 – Defective B cell development in the bone marrow of GPS2-BKO mice 
results from GPS2 regulation of AKT activation and direct transcriptional control. 
(A) GPS2 mRNA expression in BM B cells from GPS2-BKO and control littermates 
measured by RT-qPCR. (B) Western blotting analysis for P-AKT (Ser 473) and P-
FOXO1 in splenic B cells. (C) Down regulation of BLNK1, RAG1, RAG2, and FOXO1 
in BM from GPS2-BKO and control littermates by RT-qPCR. Bar graphs represents the 
sample mean of three independent experiments +/- SD. (D) Chromatin 
immunoprecipitation (ChIP) analysis to measure GPS2 occupancy on the promoters of 
putative target genes in B cells purified from BM of WT mice. (E) ChIP for GPS2 and 
FOXO1 in B cells purified from BM of either WT or GPS2-BKO mice. For ChIPs, data 
are representative of three independent experiments. Bar graphs represents the sample 
mean of technical replicates +/- SD; * indicate p-value<0.05; ** indicate p-value<0.01.). 
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FOXO1 in GPS2-BKO B cells, we found that FOXO1 binding on target gene promoters 
was drastically reduced in GPS2-BKO cells (Figure 3.16E). Interestingly, the expression 
of FOXO1 gene itself was also found significantly downregulated in GPS2-depleted cells 
(Figure 3.16C). Thus, we asked whether GPS2 regulated the transcription of these genes 
directly as well. Results of our chromatin immunoprecipitation analysis revealed 
significant GPS2 binding to the promoters of BLNK, RAG1, RAG2 and FOXO1 genes in 
WT B cells isolated from the bone marrow (Figure 3.16D). In turn, we observe 
significantly less GPS2 binding on these promoters thus suggesting a direct role for GPS2 
in the transcriptional forward loop that regulate FOXO1 and some of its target genes in 
developing B cells (Figure 3.16E). These results strongly confirm that the role of GPS2 
in regulating AKT phosphorylation and activation is a conserved mechanism in various 
cell types yet also suggests that GPS2 direct transcriptional control of FOXO1 could have 
a function in GPS2-AKO adipocytes as well (Figure 3.17).  
Discussion 
Insulin action is critically required for promoting cell growth, regulating tissue 
development, and controlling whole body metabolism through modulation of glucose 
homeostasis and lipid metabolism. It’s disruption or reduced functionality leads to the 
development of insulin resistance, a hallmark of Type 2 Diabetes and other metabolic 
disorders. The signaling mechanisms that mediate the physiological responses to insulin 
have been thoroughly studied with the identification of multiple transduction pathways, 
including both positive and negative regulators. Major players in these pathways are 
kinases, which are usually counter-regulated by opposing phosphatases (i.e. PI3K and 
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PTEN). Our work has further extended this signaling network by revealing the existence 
of an additional level of regulation based on the opposing actions of an ubiquitin 
conjugating enzyme, Ubc13, and its endogenous inhibitor, GPS2.  Insulin-mediated 
ubiquitination of AKT, via Ubc13-mediated synthesis of K63 ubiquitin chains, is an 
unexpected, critical step for the activation of downstream signaling events (Figure 
3.17A). Non-proteolytic ubiquitination of AKT had been previously reported for growth 
factor-mediated pathways, and a cancer-associated mutation that affects the 
ubiquitination of AKT1 (E17K) had been linked to AKT hyperactivation in breast and 
colon cancer. In this context, the gain of an additional lysine in the PH domain was found 
to promote enhanced AKT ubiquitination, constitutive recruitment to the membrane and 
activation 36,43,161. Interestingly, exome sequencing of patients with severe hypoglycemia 
but undetectable plasma insulin has recently led to the identification of a homologous 
activating mutation in AKT2 that might be similarly promoting enhanced ubiquitination. 
Overexpression of the E17K mutant in 3T3-L1 preadipocytes promoted insulin-
independent localization of both AKT and GLUT4 to the plasma membrane and nuclear 
export of FoxO1, indicating constitutive activation of the AKT signaling pathway 45,162. 
These observations support our findings that regulation of AKT activation by 
ubiquitination is a conserved feature among the metabolic and growth signaling pathways 
mediated by different AKT isoforms. They also indicate that the non-proteolytic 
ubiquitination of AKT represents a key regulatory node for both adipose tissue and 
systemic homeostasis and metabolism. 
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Figure 3.17 – Model of GPS2 regulation of AKT. 
(A) Model of GPS2 regulation of the insulin signaling pathway in adipocytes. (B) Model 
of GPS2 regulation of AKT in B cells.  
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In addition to revealing a role for K63 ubiquitination in the insulin pathway, our 
work has identified GPS2 as an endogenous inhibitor of this regulatory step. We 
previously characterized GPS2 as an inhibitor of Ubc13/TRAF2-6 activity in the context 
of pro-inflammatory pathways downstream of TNFa and TLR receptors 84. Here, we 
confirm that a significant increase in JNK activation in primary adipocytes is observed 
upon GPS2 deletion. We also report the novel finding that GPS2 is a critical player in the 
insulin transduction pathway. Our data, in particular, reveal that physiological levels of 
GPS2 in adipocytes are required for preventing the constitutive ubiquitination of AKT, 
and therefore restricting its activation, as well as the activation of downstream signaling 
events, when insulin levels are low. In accord with these conclusions, we found that 
GPS2 deletion in mice adipose tissue results in constitutive ubiquitination and activation 
of AKT, leading to disrupted lipid metabolism and increased adiposity, but also elevated 
adiponectin levels. Interestingly, overexpression studies in mice indicate that increasing 
the level of secreted adiponectin contributes to mimicking a state of constant feeding and 
results in improved insulin sensitivity despite the substantial expansion of the adipose 
tissue  9,142,158. Similarly, deletion of PTEN, a well-known inhibitor of AKT, promotes 
sustained insulin signaling and improved insulin sensitivity despite a significant increase 
in body weight 142. Our results indicate that the absence of GPS2 similarly favors the 
retention of triglycerides in the adipose tissue, and thus improvement of insulin 
sensitivity in mice that become obese when fed a regular laboratory chow diet.  
Interestingly, our previous work showed GPS2 playing an important anti-
inflammatory role in the regulation of pro-inflammatory signaling pathways. GPS2 anti-
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inflammatory role was then confirmed by macrophage-specific and B-cell-specific 
deletion studies, and by GPS2 overexpression in the adipose tissue (both adipocytes and 
macrophages) of DIO obese mice 84,85,163. In contrast, we report here that GPS2 adipo-
specific deletion has a positive effect on adipocyte insulin signaling and systemic insulin 
sensitivity in chow-fed mice, and that, under these conditions, inflammation of the 
adipose tissue is undetectable in GPS2-AKO mice despite their increase in body fat. 
These observations are in agreement with a recent report that hyperinsulinemia can drive 
adipose tissue inflammation whereas a reduction in circulating insulin levels causes a 
decrease in the expression of pro-inflammatory markers and macrophage expansion in 
the adipose tissue 164. Thus, our findings reveal that GPS2 plays an intriguing role at the 
intersection between inflammatory and metabolic pathways, and suggest that sustained 
AKT activation through enhanced ubiquitination is likely to overcome the negative effect 
that the elevated levels of P-JNK might have on insulin signaling via IRS1 
phosphorylation. Finally, it is important to note that there are layers to the phenotype 
associated with the loss of GPS2 function that might depend on the genetic background 
and the experimental conditions. For example, while the GPS2-AKO mice described here 
become obese even when fed a chow diet, similar mice generated by Fan and colleagues 
were not obese at baseline and did not appear to gain extra weight upon HFD feeding. 
Thus, further studies that explore the interplay between increased activation of pro-
inflammatory signaling pathways and enhanced insulin signaling in GPS2-AKO mice 
will be critical for a comprehensive understanding of the crosstalk between these 
pathways in condition of diet- or genetic-induced obesity. Interestingly, our results 
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indicate that the synergistic roles played by GPS2 in the regulation of JNK activity and 
insulin signaling are mediated through a conserved mechanism based on the inhibition of 
Ubc13 enzymatic activity. This raises the interesting question of whether the 
ubiquitination machinery responsible for the synthesis of non-proteolytic K63 ubiquitin 
chains represents a key regulatory node between inflammation and lipid metabolism at 
the onset of obesity.  
Lastly, it is worth noting that there is a large body of work describing GPS2 as a 
transcriptional cofactor, involved in mediating both gene repression, as part of the 
NCoR/SMRT complex, and activation, through direct interaction with nuclear receptors 
and other TFs 89,90,92,93,96,105. For example, in the adipose tissue, downregulation of GPS2 
was associated with the derepression of inflammatory target genes in human obese 
patients 97, and with the activation of key enzymes for triglyceride breakdown, HSL and 
ATGL, in murine differentiating adipocytes 79. Here, we have confirmed a critical role for 
GPS2 in the regulation of adipocyte triglyceride turnover. However, the expression of 
HSL and ATGL was not impaired in GPS2-null primary adipocytes, indicating that 
lipolysis is likely suppressed due to the sustained activation of insulin signaling even 
under baseline or fasted conditions, rather than direct transcriptional effects. Thus, our 
previous and current findings, together, indicate that while GPS2 is essential for the early 
development of preadipocytes, its deletion at later stages does not affect differentiation 
but GPS2 remains essential for maintaining metabolic homeostasis in mature adipocytes. 
Intriguingly, increased adiposity and altered lipid mobilization have been previously 
reported also in the case of mice lacking a binding partner of GPS2, the transcriptional 
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corepressor TBLR1.The phenotype observed upon TBLR1 deletion appears to similarly 
extend beyond the transcriptional regulation of HSL and ATGL, with TBLR1 being 
described as required for controlling multiple steps of the lipolytic cascade, including 
both changes in gene expression and a decrease in the phosphorylation of HSL and other 
PKA substrates 165. This suggests that multiple components of the NCoR/SMRT 
corepressor complex might play complementary genomic and non-genomic functions 
towards the coordinated regulation of cell homeostasis. 
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CHAPTER FOUR – GPS2 REGULATES MITOCHONDRIA AND BROWN 
ADIPOSE TISSUE FUNCTION 
This chapter is adapted from Cardamone, M.D., Cederquist, C.T.*, Tanasa, B.*, Huang, 
J., Mahdaviani, K., Li, W. Rosenfeld, M.G., Liesa, M., and Perissi, V. GPS2 regulates 
mitochondria biogenesis via mitochondria retrograde signaling and chromatin remodeling 
of nuclear-encoded mitochondrial genes. Under review. 
*= These authors contributed equally to this work.  
Abstract 
 Brown adipose tissue (BAT) is a specialized type of adipose tissue (AT) 
containing multiple small lipid droplets and an extremely high density of mitochondria. 
This depot is characterized by high expression of the uncoupling protein (UCP1) which 
allows BAT to burn fatty acids for the generation of heat rather than ATP production. 
These features allow BAT to be specifically involved in energy control and 
thermoregulation. Dysfunctionality of this tissue has been associated with metabolic 
diseases and, in turn, therapeutics to increase BAT activity are under investigation to 
target Type 2 diabetes and metabolic syndrome.  
Mitochondrial biogenesis and homeostasis are critically important for the function 
of BAT. Because most mitochondrial proteins are encoded in the nuclear genome, these 
functions are directly dependent on the regulation of gene transcription in the nucleus. 
Studies performed in vitro in 3T3-L1 cells have revealed that GPS2 is required for the 
transcriptional activation of a vast nuclear-encoded mitochondrial gene program. This 
suggested that GPS2 transcriptional functions in vivo will be particularly relevant in the 
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context of BAT. In addition, our previous work has shown that GPS2 plays an essential 
role in the balance of lipid storage capacity by regulating lipolysis and lipogenesis in 
WAT, suggesting a similar phenotype may be observed in BAT as well.   
Indeed, in our phenotypic analysis, we observe that the regulatory strategies in 
which GPS2 is essential for supporting mitochondrial biogenesis and lipid storage are 
conserved in BAT from GPS2-AKO mice. Specifically, we found that loss of GPS2 in 
these mice led to impaired mitochondria biogenesis, which in concordance with impaired 
lipolysis, resulted in whitening of this AT depot. Together, our study shows that 
modulation of GPS2 in BAT represents a critical node for the coordinated regulation of 
metabolic pathways modulating the balance between lipid storage and energy 
expenditure. 
Introduction 
Brown adipose tissue (BAT) is a distinct, specialized type of adipose tissue that is 
found to play a critical role in energy homeostasis. The tissue derives its name and color 
due to high mitochondrial content and extensive vascularization. It was initially thought 
to be abundant only in newborns or small mammals, naturally susceptible to loss of heat, 
as a mechanism to adequately maintain body temperature. However, it was recently 
found that adult humans also have metabolically active BAT, found distributed in various 
regions of the body such as cervical, supraclavicular, axillary, paravertebral, and upper 
abdominal locations166,167. The discovery of adult BAT has led to more extensive 
research on the development and function of this specialized AT depot.  
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Classic brown fat is derived during embryogenesis from mesenchymal precursors 
of a Pax7+ and Myf5+ lineage, similar to skeletal muscle, unlike classic WAT which 
arises from a Pax7- and Myf5- lineage168-171. Through these studies, another 
developmentally distinct type of brown fat was uncovered, known as beige/brite adipose 
tissue172-175. This type of BAT is recruited postnatally through either a mechanism of 
transdifferentiation of mature white adipocytes into a brown adipocyte-like phenotype or 
by induction of brown-like specific progenitors, which is still under investigation176-179. 
Despite differences in developmental origin, BAT also acts as an endocrine organ and 
can release various factors such as IGF1, IL6, and FGF21 similarly to the endocrine 
capabilities of WAT. Both AT depots are therefore critical for the regulation of systemic 
metabolism. 
The differences in function of BAT versus WAT have been broadly studied as 
well. Whereas white adipocytes comprised of a large, unilocular lipid droplet are 
predominantly used for energy storage, brown adipocytes contain small, multilocular 
lipid droplets, densely packed mitochondria and specifically express uncoupling protein 
1, UCP1. BAT also has a distinct gene expression signature from WAT that includes high 
expression of PGC1a, PRDM16, PPARa, CIDEA, ELOVL3 and DIO2. This gene 
expression program also includes enhanced expression of genes involved in 
mitochondrial biogenesis and function170,175,180-182. These characteristics are required for 
the primary function of this depot to regulate thermogenesis and energy expenditure.  
Proper functionality and response of BAT to external and internal metabolic 
signals consequently relies heavily on appropriate mitochondria function and plasticity of 
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mitochondrial biogenesis. Mitochondria are highly dynamic, cytoplasmic organelles with 
distinct compartments: outer membrane, inner membrane, intermembrane space, cristal 
membranes, intracristal space and a matrix183,184. This organelle is involved in almost all 
metabolic pathways, however the most distinctive, crucial role is to synthesize a majority 
of cellular ATP used as energy currency. This process requires the oxidation of nutrients 
into Acetyl-CoA which enter the citric acid (TCA) cycle producing high energy electrons 
that feed into the various complexes of the electron transport chain (ETC). As these 
reactions proceed, energy released causes protons to get pumped out of the mitochondria 
matrix space and create a pH gradient which helps to drive ATP synthase activity and the 
production of ATP from ADP via phosphorylation183,184. Additionally, mitochondria 
contain their own small genome, however most mitochondrial proteins are encoded by 
nuclear DNA, synthesized in the cytoplasm and imported into mitochondria183,184. This 
system relies heavily on exquisite communication between these organelles because in 
response to various metabolic conditions, mitochondria can increase or decrease their 
number or undergo remodeling via fission and fusion to adapt to the energy demands of a 
cell170,175,180-182. For example, the proper expansion of mitochondrial mass and increased 
functionality of mitochondria-specific metabolic pathways has been shown to be 
important for the process of adipogenesis. 
The multilocular lipid droplets in BAT allow for the rapid release of free fatty 
acids (FFAs) from triglyceride stores to be burned by mitochondria that uniquely contain 
UCP1. UCP1 acts as a proton channel that causes dissipation of the proton gradient 
formed in the inner mitochondrial membrane from the products of oxidative 
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phosphorylation of nutrient stores. This causes a proton leak allowing UCP1-rich 
mitochondria to generate heat rather than ATP, the complete process known as non-
shivering thermogenesis170,175,180-182. BAT can become even more active in response to 
various stimuli, which include B adrenergic agonist stimulation or cold exposure. These 
stimuli induce the release of norepinephrine from the sympathetic nervous system (SNS) 
to significantly increase UCP1 and other brown fat specific and mitochondria genes 
ultimately triggering enhanced BAT activation. Additional stimuli such as cAMP 
analogs, thyroid hormone, insulin, thiazolidinediones, and retinoic acid can also 
contribute to BAT activation170,175,180-182. Overall, UCP1 uncoupling activity and 
mitochondrial function have been shown to be essential for BAT-mediated maintenance 
of thermogenesis as well as the induction of browning in WAT depots.  
Mitochondria also clearly play a central role in regulating metabolism of both AT 
depots via documented roles in affecting lipolysis and lipogenesis. Lipolysis allows for 
the breakdown of free fatty acids (FFAs) that can diffuse or travel through carnitine 
shuttles into the mitochondrial matrix whereby the FFAs are converted to Acetyl-CoA via 
beta oxidation to be further used in the TCA cycle and ETC. Mitochondria, in turn, have 
the ability to provide key intermediates, such as glycerol 3-phosphate, Acetyl-CoA, and 
pyruvate, for the processes of de novo lipogenesis and triglyceride synthesis13,183-185.  
Mitochondria dysfunction in both brown and white adipocytes has been recently 
associated with metabolic dysfunction. Mitochondrial dysfunction resulting in impaired 
oxidation of fuels and lipid accumulation are associated with obesity and insulin 
resistance however the direct role of AT mitochondria in the development of these 
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pathologies is still under stringent investigation186-188. One example shows that defects in 
the electron transport chain can result in increased reactive oxygen species, which can 
interfere with proper adipocyte function in the maintenance of glucose homeostasis and 
adipokine secretion189,190. Due to the significant capacity of BAT to dissipate energy 
which requires the catabolism of triglycerides and glucose, brown fat is thought to be a 
potential, potent target for the treatment of obesity- associated disorders191,192. Therefore, 
an increase in the fundamental knowledge about the regulation of BAT formation and its 
activity is necessary to determine its full therapeutic potential.  
We have shown that GPS2 is a multi-functional protein that recently emerged as 
an important regulator of inflammation and lipid metabolism, all processes tightly linked 
to mitochondrial functions79,84,89,91,97. In addition, we have also identified a direct 
mechanism in which GPS2 controls mitochondria, independently of regulation of signal 
transduction of metabolic pathways. Although GPS2 was previously reported in both the 
nuclear and cytosolic compartments84, we have revealed that GPS2 is a previously 
unrecognized mitochondrial protein. In these studies, we have shown that after induction 
of mitochondrial stress inducing mitochondrial biogenesis, GPS2, via de-sumoylation by 
SENP1, was able to translocate from the outer mitochondrial membrane into the 
nucleus94,193-196. GPS2 was recruited specifically on nuclear-encoded mitochondrial gene 
promoters and affected the processivity of core transcription machinery, including Pol2 
processivity (Figure 4.1). In agreement with these findings, GPS2 downregulation 
(GPS2-KD) in 3T3-L1 preadipocytes was associated with a significant reduction in  
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Figure 4.1 – Model of GPS2 regulation of mitochondrial retrograde signaling in 
3T3-L1 adipocytes.  
Upon mitochondrial stress, GPS2 is de-sumoylated on the outer mitochondrial membrane 
and translocates into the nucleus where it can regulate core transcription machinery on 
mitochondria gene promoters. 
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mitochondrial mass and mitochondrial gene expression, thereby affecting the respiration 
capacity of GPS2-KD cells. 
Together, these results confirm that GPS2 plays a major role as a mediator of 
mitochondria retrograde signaling which is important in promoting biogenesis of new 
mitochondria through the activation of an extensive mitochondrial gene program. This 
data all raised the question of how GPS2 affects mitochondrial function and biogenesis in 
vivo. Therefore, we sought to investigate the role of GPS2 in regulating BAT, a 
mitochondria-rich tissue, using GPS2-AKO mice. Our data in this model suggests that 
this newly identified role of GPS2 is physiologically relevant and loss of GPS2 results in 
dysfunctional brown adipose tissue.  
Results 
GPS2-AKO mice display decreased mitochondrial function in brown adipose tissue 
To complete our investigation of the GPS2-AKO mice, we next decided to 
investigate the specific phenotype of BAT. We first confirmed that GPS2 was absent in 
this AT depot (Figure 4.2A). In WAT of GPS2-AKO mice, we showed that adipocytes 
had significantly impaired lipolysis86. We find this mechanism of lipid utilization is also 
impaired in BAT by measuring the activation of HSL (Figure 4.2B). We also showed 
that the sumoylated form of GPS2, which controls ints translocation to the nucleus is 
expressed in BAT and as expected this form in absent in GPS2-AKO BAT (Figure 
4.2A). The removal of GPS2 from BAT led to a significant decrease in nuclear-encoded 
mitochondria gene expression (Figure 4.2C). These results suggest the mechanisms of  
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Figure 4.2 – GPS2-AKO mice have impaired lipolysis and mitochondrial gene 
expression in the brown adipose tissue.  
(A) WB analysis of GPS2 using two independent antibodies in WT versus GPS2-AKO 
mice normalized to B tubulin expression. (B) WB analysis of phospho-HSL/total HSL in 
whole cell extracts of brown adipose tissue in GPS2-AKO versus WT mice after 
overnight fasting. (C) RT-qPCR analysis of mitochondrial and brown fat specific gene 
markers, in BAT of GPS2-AKO versus WT mice, n= 4-5. Results are expressed as mean-
/+SEM. Statistical significance was calculated by two-tailed Student’s t test; * represents 
p value <0.05 and ** p value < 0.01. All western blots are representative images of at 
least three independent experiments. 
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GPS2 in regulating lipid storage capacity and in mediating mitochondria retrograde 
signaling are preserved in BAT.  
The mechanism described in vitro in 3T3-L1 cells showed that knockdown of 
GPS2 resulted in impaired mitochondria biogenesis. To determine whether this 
phenotype was conserved in vivo, we first measured the number of mitochondria in the 
tissue and found mitochondria content was significantly decreased in GPS2-deficient 
mice (Figure 4.3A). In agreement with these results, it was also observed that the whole 
tissue had decreased levels of various subunits of each complex of the oxidative 
phosphorylation pathway (Figure 4.3B). On the contrary, respiration measured in 
mitochondria isolated from BAT was unaffected by the loss of GPS2 (Figure 4.3C). 
Together, these data indicate that mitochondria biogenesis was defective BAT of GPS2-
AKO mice however the functionality of the remaining mitochondria in the tissue were 
not impaired per se. These results confirmed that GPS2 regulates nuclear-encoded 
mitochondria gene expression and mitochondria biogenesis in BAT.  
GPS2-AKO mice display increased lipid accumulation in brown adipose tissue and in 
in vitro differentiated brown adipocytes  
Mitochondria dysfunction and impaired biogenesis197 as well as impaired lipolysis 
have been associated with whitening of BAT198. As described above, GPS2 deletion in 
WAT has been recently reported to promote obesity associated with increased deposition 
of lipids in the WAT and improved systemic insulin sensitivity86. In agreement with the 
impaired lipolysis and compromised mitochondria biogenesis observed in BAT from 
GPS2-AKO mice, histological inspection revealed that GPS2 deletion promotes the  
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Figure 4.3 – GPS2-AKO mice have impaired mitochondria biogenesis in the brown 
adipose tissue.  
(A) Mitochondrial mass calculated by mtDNA/gDNA content, n=4-5. Results are 
expressed as mean-/+SEM. (B) WB analysis of various comlexes in the electron transport 
chain in whole cell extracts of brown adipose tissue from GPS2-AKO versus WT mice 
after fasting normalized to HSP70. (C) Quantification of oxygen consumption rates 
(OCR) in BAT isolated mitochondria from control and GPS2-AKO mice in chow diet 
under the different respiratory states. State 2 quantifies respiration driven by proton leak, 
state 3 quantifies respiration linked to maximal ATP synthesis and maximal represents 
maximal electron transport chain activity induced by FCCP.  Bar graphs represent 
average ± SEM for complex I-driven respiration (pyruvate-malate, n=6 mice per group), 
complex II-driven respiration (succinate-rotenone, n=6 mice per group). Statistical 
significance was calculated by two-tailed Student’s t test; * represents p value <0.05 and 
** p value < 0.01. All western blots are representative images of at least three 
independent experiments. 
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whitening of this depot (Figure 4.4A). Confirming these results, adipocytes arising from 
differentiation of SVF from BAT of GPS2-AKO mice contain larger lipid droplets than 
adipocytes derived from WT SVF (Figure 4.4B). Together, these results suggest the role 
of GPS2 in regulating mitochondria biogenesis through mediating mitochondrial 
retrograde signaling to control nuclear-encoded mitochondria gene expression is 
physiologically relevant. Furthermore, GPS2 control of mitochondria biogenesis and 
lipolysis led to a whitening of GPS2-AKO mice BAT.  
Discussion 
In conclusion, we have characterized the GPS2-AKO mouse by dissecting how 
the physiology of BAT is affected by loss of GPS2. Particularly, GPS2-AKO mice have a 
dysfunctional BAT depot with reduced mitochondria biogenesis, decreased lipolysis, and 
a whitened phenotype. We have confirmed that the role of GPS2 in regulating lipid 
storage capacity in WAT is also conserved in brown fat. Moreover, our results together 
confirm the in vivo relevance of GPS2 in regulating the transcriptional activity of 
nuclear-encoded mitochondrial gene expression for the proper regulation of 
mitochondrial biogenesis. 
These in vivo data indicate that GPS2 plays a critical role in regulating lipid 
metabolism and energy expenditure in BAT. More investigation into the mechanisms 
leading to mitochondrial dysfunction in WAT depots should be undertaken since such 
dysfunction is linked to obesity-associated insulin resistance. It will be important to 
determine whether the mechanisms by which GPS2 regulates mitochondrial homeostasis 
contribute to the increased lipid storage capacity in WAT depots and additionally whether  
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Figure 4.4 – GPS2 deficiency in brown adipose tissue results in a whitening 
phenotype in the tissue depot and in vitro differentiated brown adipocytes compared 
to WT mice.  
(A) Representative H&E staining of BAT of  WT and GPS2-AKO mice showing 
increased lipid deposition in the GPS2-AKO mice compared to WT mice under 10X 
magnification. (B) Representative Oil Red O staning of in vitro differentiated SVF from 
brown adipose tissue of WT versus GPS2-AKO mice.  
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they help to drive the decreased lipolysis and increased lipogenesis observed in the 
GPS2-AKO mice.  
In addition, the phenotype observed in the BAT of GPS2-AKO mice raises the 
question of whether GPS2 could affect the browning process in WAT depots. Browning 
is the process by which certain white adipose tissue depots can take on a brown fat 
phenotype when subjected with certain stimuli174,175,199-201. These stimuli include chronic 
cold exposure, B-adrenergic stimulation, or pharmacological treatments such as PPARg 
agonists. These effectors induce white adipocytes to either adopt a brown fat gene 
expression program or turn on this BAT gene expression program in newly recruited and 
differentiated beige/brite adipocytes. Once activated, these beige/brite cells possess many 
characteristics of classical brown fat including the presence of multiple mitochondria and 
multiple lipid droplets. UCP1 levels significantly increase and genes related to 
mitochondrial biogenesis are also increased which allow the cells to participate in 
adaptive thermogenesis and energy expenditure174,175,199-201. Because GPS2 is required for 
normal mitochondrial function in BAT, one would expect that its loss in beige/brite 
adipocytes of WAT would prevent these cells from participating in thermogenesis and 
energy expenditure. Additionally, the absence of GPS2 would also lead to defective 
lipolysis in these cells and consequently a reduction in fatty acids that fuel thermogenesis.  
Intriguingly, mitochondria dysfunction has been shown to contribute to insulin 
resistance in many ways202,203. A decreased number of mitochondria, decreased 
mitochondrial gene expression, abnormal morphology and impaired functions in 
oxidative phosphorylation are commonly found aberrations in insulin-resistant metabolic 
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tissues, including adipose tissue, skeletal muscle and liver. These mitochondria 
abnormalities are associated with intracellular lipid accumulation, insulin resistance, and 
the overall pathophysiology of T2D204-206. Despite these data, this phenomenon is not 
observed in GPS2-AKO mice on chow or HFD. In fact, GPS2-AKO mice have improved 
glucose and insulin tolerance. This observation raises many interesting questions. The 
first being whether mitochondrial function is directly related to the progression of insulin 
resistance or is a secondary effect of improper energy partitioning. If it is a primary 
determinant in disease progression, how exactly do dysfunctional mitochondria 
contribute to insulin resistance and can the dysfunction be by-passed by maintain the 
correct balance of lipid storage versus lipolysis. Further investigation is necessary to 
answer these questions and shed light on whether modulating mitochondrial function 
could help improve metabolic diseases.  
Lastly, it is worth noting that both mitochondrial function and BAT activity 
decline with age. Specifically, humans and rodents lose their ability to regulate body 
temperature13. This decline in thermoregulation is often related to BAT atrophy and a loss 
of UCP1 activity180,207. In an investigation of the effect of aging on BAT activity in lean 
and obese mice, it was found that old obese animals exhibited decreased expression of 
UCP1, BAT thermogenic capacity and overall BAT activity208. Our novel findings 
showing that mitochondrial biogenesis is regulated by GPS2 raises the possibility that it 
is a target for development of therapeutics to treat age-associated diseases, most notably 
those affecting mitochondrial-rich tissues such as the brain. 
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CHAPTER FIVE – GPS2 MODULATES THE INTERPLAY BETWEEN 
ADIPOSE TISSUE INFLAMMATION AND SYSTEMIC METABOLIC HEALTH 
STATUS 
Abstract 
 Obesity- associated inflammation is widely recognized as a critical factor in the 
development of insulin resistance leading to Type 2 diabetes (T2D) and other metabolic 
disorders. In response to obesity, adipose tissue (AT) becomes dysfunctional and 
increases the production of pro-inflammatory cytokines. This can drive infiltration of 
immune cells into AT and the development of systemic, low-grade, chronic inflammation 
associated with insulin resistance. However, surprisingly, treatment with anti-
inflammatory drugs has not proven successful in treating these metabolic syndromes and 
the critical question of whether inhibiting inflammation is a good approach in the attempt 
to treat insulin resistance remains unanswered.  
While characterizing the GPS2-AKO mice, we found that adipocytes had 
increased cell size, resulting in increased fat mass and total body weight. Typically, 
obesity is associated with increased inflammation and metabolic dysfunction, however 
these phenotypes were not observed in GPS2-AKO mice on chow diet, which instead 
showed improved insulin signaling. This suggested that obesity could be uncoupled from 
inflammation and whole body metabolism in the presence of sustained AT insulin 
signaling. However, these observations are in contrast with previous reports that GPS2 
plays an important anti-inflammatory role in various metabolic organs. GPS2 is found to 
inhibit signal transduction of TNFa and TLR pathways as well as act as a cofactor 
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regulating gene expression by inhibiting transcription of pro-inflammatory targets. 
Because of the anti-inflammatory role of GPS2, we hypothesize that a lack of GPS2 in 
AT under excessive nutrient stress could result in increased inflammation leading to a 
decline in systemic metabolism.  
In order to further our characterization of GPS2-AKO mice, we exposed the mice 
to a high fat diet (HFD) regimen to dissect the critical role of GPS2 in regulating obesity-
induced inflammation and lipid metabolism in vivo. Unexpectedly, we observe that the 
GPS2-AKO mice become more obese and inflamed than WT mice during HFD feeding 
yet are protected from developing insulin resistance. Our data suggests that increased AT 
lipid storage capacity and a reduction of peripheral lipid deposition has a positive, 
protective role against the development of insulin resistance, despite increased 
stimulation of inflammatory responses in AT. We hypothesize the role of GPS2 in 
controlling macrophage infiltration could potentially lead to healthy tissue remodeling 
and expansion. The GPS2-AKO mice represent a unique model to improve our 
comprehension of the interplays between inflammation and adipose tissue functionality in 
the development of insulin resistance and this work contributes to understanding whether 
inhibiting inflammation in the context of obesity is a viable strategy to ameliorate 
metabolic functionality.  
Introduction 
 Adipose tissue is a highly active organ involved in numerous metabolic and 
immune processes. AT function and secretory abilities are able to act locally as well as 
influence other organs systems that play crucial roles in the regulation of whole body 
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homeostasis. Obesity-associated insulin resistance can drive a phenotype of low-grade 
chronic inflammation. Specifically, dysfunctional AT propagates the secretion of 
chemoattractants such as MCP-1 and pro-inflammatory cytokines such as IL-6, TNFa, 
and IL1B, which increase immune cell infiltration into AT, most notably macrophages. 
Macrophages with either an M1 or M2 phenotype can elicit either pro-inflammatory or 
anti-inflammatory responses respectively209, and M1 pro-inflammatory macrophages are 
predominately recruited under conditions of obesity210. Moreover, dysfunctional AT lipid 
metabolism leads to increased circulating FFAs which further initiates pro-inflammatory 
signaling cascades in recruited immune cells. It has been found that these cumulative 
signaling events cause a feedback loop of pro-inflammatory cytokines exacerbating the 
AT pathological state by continuously disrupting the insulin signaling cascade in 
adipocytes. AT dysfunction and induction of inflammation can further cause defects in 
hepatic and skeletal muscle glucose homeostasis, resulting in systemic insulin resistance 
and the development of T2D. A plethora of reports have shown that obesity- associated 
inflammation strongly correlates with increased insulin resistance however anti-
inflammatory drug therapies have proven unsuccessful in treating metabolic 
diseases51,58,211-218. 
Thus, an open question remains whether the recruitment of the immune system in 
the context of obesity is solely a pathological process. In this regard, it has been proposed 
that the presence of immune cells in metabolic organs, such as AT, help to support the 
physiologic function of these metabolic tissues. In support of this idea, recent reports 
have shown that macrophage infiltration in AT is required for proper tissue expansion 
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and remodeling 66,219,220. Specifically, local inflammation has been shown to act as an 
adaptive response for AT expansion to permit storage of excess nutrients66. Immune cell 
infiltration, in the context of obesity, also allows macrophages to play an important role 
in lipid trafficking and uptake to reduce lipotoxicity221.  Local inflammatory responses 
have been shown to be required to recruit progenitors as well as allow for enhanced 
adipogenesis in order to deal with increased lipid load as well222,223. Therefore, it is clear 
that inflammation is important for the homeostasis of AT, yet becomes a 
pathophysiologic signal when lipid load and inflammatory signaling become 
uncontrollable. 
GPS2 plays an important anti-inflammatory role in metabolic organs, specifically 
adipose tissue84,224. Reports in human studies show an inverse correlation between GPS2 
and adiposity and markers of AT inflammation, specifically IL6 97. This was attributed to 
the function of GPS2 to repress pro-inflammatory genes as part of the NCoR/SMRT 
corepressor complex. Additionally, our lab has shown that cytoplasmic GPS2 acts to 
inhibit both the TNFa and TLR signaling pathways by inhibiting ubiquitination events 
required for downstream signaling thereby blocking JNK activation 84,85. The in vivo 
relevance of this GPS2 function was first demonstrated in aP2 driven GPS2-TG mice by 
showing these mice are protected from HFD- induced increases in AT inflammation, 
providing additional proof that GPS2 has an anti-inflammatory function in adipocytes. 
TG mice showed decreased phosphorylation of JNK and decreased expression of pro-
inflammatory markers in AT. Very surprisingly however, these mice did not have 
improvements in systemic metabolism as measured by glucose and insulin tolerance tests.  
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Figure 5.1 – GPS2-AKO mice gain significantly more total body weight on high fat 
diet.  
(A) Body weight gain of WT versus GPS2-AKO mice after 16 weeks of 45% HFD 
feeding regimen. (B) Body weight gain curve measured weekly during 16 weeks of HFD 
in WT versus GPS2-AKO mice, n=3. Results are expressed as mean -/+ SEM. Statistical 
significance was calculated by two-tailed Student’s t test; *represents p value < 0.05 and 
**p value < 0.01. 
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These data suggest that there is an uncoupling between lipid metabolism and 
inflammation during the onset of insulin resistance. Therefore, there is still a great deal to 
be learned about the possible beneficial effects of inflammation in protecting from 
systemic metabolic dysfunction.  
In order to further elucidate the relationship between lipid metabolism and 
inflammation on metabolic flexibility, the characterization of GPS2-AKO mice was 
expanded to understand their phenotype on HFD. This is an interesting model to use 
because GPS2-AKO mice become obese even under conditions of chow diet yet remain 
metabolically healthy, due to enhanced AT insulin signaling controlling triglyceride 
handling86. However, removal of GPS2, which has been shown to control key 
inflammatory signaling cascades, presumably would result in increased AT 
inflammation. Our initial results show that GPS2-AKO mice on HFD become more obese 
and inflamed than WT mice, however continue to show improved systemic metabolism 
while WT mice develop insulin resistance. By further studying GPS2-AKO mice on HFD 
we hope to dissect the relevance and interplay among inflammation and lipid storage in 
the development of insulin resistance.  
Results 
GPS2-AKO mice display increased adiposity without signs of enhanced peripheral lipid 
deposition on high fat diet 
During the 16 weeks on a 45% HFD, both WT and GPS2-AKO mice gained a 
significant amount of weight, however, GPS2-AKO mice gained significantly more body 
weight than WT mice (Figure 5.1A). Similar to observations of GPS2-AKO mice on  
		
120 
 
Figure 5.2 – Increased adipose tissue size and mass are observed in GPS2-AKO mice 
on HFD compared to WT mice.  
(A) Body composition analysis of total fat versus lean mass measured by EchoMRI 
scanning of WT and GPS2-AKO mice on HFD, n=2. (B) Individual adipose tissue depot 
and liver weights in GPS2-AKO versus WT mice after 16 weeks HFD, n=3. (C) 
Representative H&E staining of paraffin-embedded EPI sections from WT versus GPS2-
AKO mice after 16 weeks HFD imaged at 10X magnification. Results are expressed as 
mean -/+ SEM. Statistical significance was calculated by two-tailed Student’s t test; 
*represents p value < 0.05 and **p value < 0.01. 
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chow diet, these mice became more obese than WT counterparts upon completion of the 
HFD regiment (Figure 5.1B). The increase in body weight observed in GPS2-AKO mice 
on HFD was a result of increased fat mass, whereas no changes in mass of non-adipose 
tissues were observed (Figure5.2A-B). H&E staining of AT depots, specifically the 
epididymal (EPI) AT, suggested that the increase in AT mass in GPS2-AKO mice was in 
part due to adipocyte hypertrophy as observed by the significant increase in adipocyte 
cell size (Figure 5.2C). Interestingly, GPS2-AKO mice showed signs of reduced lipid 
deposition in the liver, suggesting that the AT depots had an expanded capacity to store 
lipids (Figure 5.3).  
The imbalance in lipid storage in GPS2-AKO mice on a chow diet could be 
explained by the observed changes in lipolysis and lipogenesis. It was also observed that 
GPS2-AKO mice had impaired lipolysis on HFD. This was determined by measuring 
ATGL and HSL gene expression in WAT depots and in isolated adipocytes from the EPI 
depot which were reduced in GPS2-AKO mice on HFD (Figure 5.4A-B). Additionally, 
there was a significant reduction in phosphorylated and activated HSL in WAT depots of 
these HFD fed mice (Figure 5.4C). Furthermore, GPS2-AKO mice on HFD had 
decreased circulating levels of free fatty acids and free glycerol (Figure 5.5A-B). These 
data suggest that GPS2-AKO mice on HFD exhibit an increased adiposity phenotype as a 
result of impaired lipolysis.  
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Figure 5.3 – Less lipid accumulation in liver of GPS2-AKO mice compared to WT 
mice on HFD.  
(A) Representative H&E staining of paraffin-embedded liver sections from WT versus 
GPS2-AKO mice after 16 weeks HFD, imaged at 10X magnification. 
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Figure 5.4 – GPS2-AKO mice have impaired lipolysis on HFD.  
(A) RT-qPCR analysis of ATGL and HSL, lipolysis markers, in EPI WAT of GPS2-
AKO versus WT mice after 16 weeks HFD, n=2. (B) RT-qPCR analysis of ATGL and 
HSL, lipolysis markers, in EPI isolated adipocytes from GPS2-AKO versus WT mice 
after 16 weeks HFD, n=2. (C) WB analysis of phospho-HSL/total HSL in whole cell 
extracts of the EPI adipose tissue depot of GPS2-AKO versus WT mice after 16 weeks 
HFD. 
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The increased AT mass observed in GPS2-AKO mice on HFD was not only 
attributed to impaired lipolysis but also a significant increase in de novo lipogenesis 
based on the increased expression of select lipogenic genes (Figure 5.6A). In an attempt 
to explain how GPS2 regulates lipogenic gene expression, we reanalyzed ChIP-
sequencing data available in the lab. In these data sets, we observed that GPS2 was 
present with the NCoR/SMRT corepressor complex on promoters of many essential 
genes involved in regulating lipogenesis in 3T3-L1 cells. In preliminary ChIP 
experiments, it was confirmed that GPS2 was present on the promoters of DGAT1 and 
FASN, which was lost in GPS2-AKO adipocytes (Figure 5.6B-C). Thess data present a 
potential mechanism of how GPS2 could coordinately regulate lipogenesis gene 
expression.  
Overall, these data show that GPS2-AKO mice on HFD have decreased lipolysis 
and increased lipogenesis. The imbalance of these pathways can thus contribute to the 
increased lipid storage observed in adipocytes resulting in increased AT mass and body 
weight.  
Removal of GPS2 results in increased macrophage infiltration and inflammation in 
adipose tissue 
Although no changes in inflammatory gene expression were observed under chow 
diet in GPS2-AKO mice, this result was very surprising considering a clear anti-
inflammatory role of GPS2 has been observed in multiple cell types84,85,224. We 
postulated that without a nutrient challenge mice would not elicit a strong induction of 
inflammation and that HFD would be a better condition to investigate AT inflammation  
		
125 
 
Figure 5.5 – GPS2-AKO mice show trends for decreased circulating free fatty acids 
and glycerol as markers of lipolysis.  
(A) Measurements of levels of circulating free fatty acids in WT versus GPS2-AKO mice 
after 16 weeks of HFD, n=2. (B). Measurements of levels of circulating glycerol in WT 
versus GPS2-AKO mice after 16 weeks of HFD, n=2. 
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in GPS2-AKO mice compared to WT mice. Therefore, we subjected mice to 16 weeks of 
45% HFD feeding. In agreement with previous reports, we found that GPS2-AKO mice 
had increased expression of inflammatory genes under HFD. We observed an 
upregulation in genes for general macrophages, M1 phenotype macrophages, as well as 
M2 macrophages in EPI AT of GPS2-AKO mice, suggesting there was not a distinct 
polarized phenotype of macrophages (Figure 5.7A-C). To understand the cell type within 
the AT depot where the expression of inflammation was most pronounced, we digested 
EPI AT and separated mature adipocytes from the SVF, where immune cells and 
precursors have been shown to reside. Through fractionation, we observed that the 
majority of the increased inflammatory gene expression came from the SVF (Figure 
5.8A). These data suggested there could be an increase in inflammatory gene expression 
in cell types residing in the SVF or it could represent an increase in the number of 
immune cells per se. We observed a significant increase in circulating levels of MCP1, 
the main chemoattractant responsible for macrophage infiltration into various tissues, 
including AT (Figure 5.8B). This observation suggested the increase in inflammatory 
gene expression is due to an overall increase in the macrophage population of the EPI 
WAT. This notion was further supported by an increased staining of the EPI depot with 
Mac2, a marker for macrophages (Figure 5.8C). Consistent with previous reports about 
GPS2 anti-inflammatory function, we have added to this body of work by reporting that 
GPS2-AKO mice have increased AT inflammation when challenged with HFD. 
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Figure 5.6 – GPS2-AKO mice have increased lipogenic gene expression potentially 
via loss of direct transcriptional control.  
(A) RT-qPCR analysis of lipogenic gene markers in WT versus GPS2-AKO mice after 
16 weeks of HFD, n=2. (B) ChIP analysis of GPS2 binding on the DGAT1 promoter in 
isolated adipocytes from WT and GPS2-AKO mice under chow diet. (C) ChIP analysis of 
GPS2 binding on the FASN promoter in isolated adipocytes from WT and GPS2-AKO 
mice under chow diet. 
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Figure 5.7 –GPS2 deficiency results in increased inflammatory gene expression in 
adipose tissue.  
(A) RT-qPCR analysis of general macrophage markers in EPI WAT from WT versus 
GPS2-AKO mice after 16 weeks HFD, n=2. (B) RT-qPCR analysis of M2 phenotype 
macrophage markers in EPI WAT from WT versus GPS2-AKO mice after 16 weeks 
HFD, n=2. (C) RT-qPCR analysis of M1 phenotype macrophage markers in EPI WAT 
from WT versus GPS2-AKO mice after 16 weeks HFD, n=2. 
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Fat-specific deletion of GPS2 results in improved systemic metabolism on high fat diet 
 Since obesity and inflammation are associated with insulin resistance, we wanted 
to understand how the severely increased adiposity and increased inflammation in GPS2-
AKO mice affected their total body metabolic parameters. Surprisingly, analysis of 
glucose tolerance tests in GPS2-AKO mice after 14 weeks on a HFD showed improved 
glucose tolerance compared to WT mice (Figure 5.9A). Comparably, fasting glucose 
levels were reduced in GPS2-AKO mice after both short and overnight fasts (Figure 
5.9B-C). Similarly, after 15 weeks of HFD, GPS2-AKO mice showed improved insulin 
tolerance (Figure 5.10A), in concert, with a reduction in fasting insulin levels in GPS2-
AKO mice compared to WT mice (Figure 5.10B). Additionally, GPS2-AKO mice had 
increased circulating levels of adiponectin, the insulin sensitizing adipokine (Figure 
5.11A), however, no changes in leptin levels were observed (Figure 5.11B). These data 
combined corroborate that removal of GPS2 in AT is protective of systemic glucose and 
insulin sensitivity, despite an increase in adiposity and AT inflammation under HFD 
conditions. 
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Figure 5.8 – GPS2-AKO mice have increased macrophage infiltration in white 
adipose tissue.  
(A) Levels of circulating MCP1 in WT versus GPS2-AKO mice after 16 weeks HFD, 
n=2. (B) RT-qPCR expression of F4/80 after digestion of mature adipocytes from SVF in 
WT versus GPS2-AKO mice after 16 weeks HFD, n=2. (C) Representative images of 
MAC2 staining for macrophage infiltration into EPI WAT in WT versus GPS2-AKO 
mice after 16 weeks HFD. DAPI staining was used for normalization. 
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Figure 5.9 – GPS2-AKO mice have improved glucose tolerance on high fat diet 
compared to WT mice.  
(A) Glucose tolerance test following glucose i.p. injection (1.5 mg/g of body weight) 
after an overnight fast in WT versus GPS2-AKO mice after 14 weeks HFD, n=3. (B) 
Fasting blood glucose levels in AKO versus WT mice after 4 hour fast at 15 weeks HFD 
GPS2-, n=3. Results are expressed as mean -/+ SEM. . (C) Fasting blood glucose levels 
in GPS2-AKO versus WT mice after overnight fast after 16 weeks HFD, n=2. 
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Discussion 
Although our studies of GPS2-AKO mice on HFD are preliminary and require 
increased cohort numbers to confirm statistical significance of many of these 
experiments, they have revealed an intriguing disconnection between obesity and AT 
inflammation in the development of insulin resistance. Specifically, we have shown that 
an increase in AT inflammation does not necessarily drive an insulin resistant state in the 
context of obesity. Intriguingly, similar reports have begun to emerge, pointing out that 
inflammation is not the sole causative factor in the progression of insulin resistance. In 
fact, inflammation has been shown to have a positive function in AT in certain contexts, 
most predominantly in the modulation of proper expansion and remodeling of the 
tissue66,219,220. In concert with our data, these results suggest that there is a disconnection 
between inflammation and adiposity in the development of insulin resistance. Further 
studies to characterize the inflammatory status of GPS2-AKO mice as well as other 
models can help shed light on the progression of when AT inflammation turns from a 
healthy response to  tissue expansion into a negative contributer to insulin resistance. 
Evolutionarily, inflammation has developed as an adaptive mechanism to fight off 
invading pathogens. Thus inflammatory mechanisms in AT appear to have adapted as a 
response to excessive nutrient intake and circulating lipids to avoid systemic 
lipotoxicity46. It has been shown that during obesity the role of macrophages is to clean 
up lipid spillover and promote lipid trafficking in states of excessive nutrient storage221. 
These data suggest that insulin resistance develops when AT inflammation reaches a 
critical level. It would be interesting to perform a stringent profiling of macrophages in  
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Figure 5.10 – GPS2-AKO mice have improved insulin tolerance compared to WT 
mice on high fat diet  
(A) Insulin tolerance test after a 0.5 U/kg body weight insulin i.p. injection in GPS2-
AKO versus WT mice following a 4 h fast after 15 weeks HFD, n=3. Results are 
expressed as mean -/+ SEM. (B) Plasma insulin levels in GPS2-AKO versus WT mice 
after overnight fast at the end of 16 weeks HFD treatment, n=2. 
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GPS2-AKO mice on HFD to understand their function and address if they are 
synergistically adding to the enhanced insulin signaling observed in GPS2-AKO mice, 
overall resulting in a more metabolically healthy mouse. 
In addition, recent reports have suggested that macrophages contribute to the 
expansion of AT by aiding in the recruitment of adipogenic progenitors222,223. It would be 
interesting to determine whether there is an increase in adipocyte progenitors of GPS2-
AKO mice following macrophage infiltration. Although we observed significant 
adipocyte hypertrophy in GPS2-AKO mice on HFD, it would be interesting and 
important to determine whether there is a corresponding increase in hyperplasia. An 
attractive hypothesis for future experimentation is that the influx of macrophages due to 
HFD initiates recruitment of progenitors with subsequent adipogenesis, which then leads 
to a healthy, insulin sensitive AT in the GPS2-AKO mice. 
Data showing that improper lipid storage, not necessarily inflammation, causes 
insulin resistance has led to the adipose tissue expandability hypothesis120,225. This 
hypothesis states that AT has a defined limit of expansion during storage of dietary 
(calories) lipid and once this limit is reached the excess lipid is deposited in other tissues 
including skeletal muscle and liver. Such ectopic lipid deposition then leads to 
lipotoxicity in those tissues that results in insulin resistance which contributes to overall 
glucose intolerance.This hypothesis has been supported by various mouse models in 
which enhanced AT expansion results in increased obesity yet the mice remain 
metabolically healthy57. Most notably, knockout of collagen 6, a highly enriched ECM 
component of adipose tissue, resulted in uninhibited, stress-free expansion of adipose  
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Figure 5.11 – GPS2-AKO mice have a trend towards an improved adipokine profile 
compared to WT mice on HFD.  
(A) Plasma adiponectin levels in WT versus GPS2-AKO mice after 16 weeks HFD, n=3. 
(B) Plasma leptin levels in WT versus GPS2-AKO mice after 16 weeks HFD, n=3. 
Results are expressed as mean -/+SEM. 
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tissue depots on either HFD or an ob/ob background226. This expansion was not 
accompanied by increased inflammation or worsening of the whole body metabolic 
profile of these mice, supporting the idea that healthy adipose tissue expansion can 
counteract insulin resistance induced by obesity57,226. Using adiponectin overexpressing 
mice, it was also found that forced expansion of adipose tissue prevents metabolic disease 
despite excessive obesity158. We would like to speculate that GPS2-AKO mice represent 
a similar model system mimicking metabolically healthy obesity. Although further 
investigation into the inflammatory profiling of GPS2-AKO mice must be done, the 
initial description of their phenotype on HFD has led to many exciting observations that 
change several paradigms in the field of obesity, metabolism and inflammation. 
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CHAPTER SIX – FUTURE DIRECTIONS, GENERAL DISCUSSION, AND 
FINAL CONCLUSIONS 
Summary of key findings  
In summary, this work has identified a novel mechanism of regulation of AKT in 
the insulin signaling pathway. Specifically, AKT undergoes Ubc13-mediated K63 
ubiquitination which is required for its activation upon insulin stimulation. This work has 
also identified GPS2 as a regulator of this process via its ability to negatively regulate 
Ubc13. GPS2-AKO mice display a phenotype of having constitutively active insulin 
signaling in WAT depots, which results in decreased lipolysis and increased lipogenesis. 
Imbalance of these pathways results in hypertrophic adipocytes, increased fat mass and 
body weight. Decreased lipolysis was also confirmed in BAT, which along with GPS2 
effect on mitochondrial biogenesis, results in whitening of this specific fat depot. 
Unexpectedly, GPS2-AKO mice remain insulin sensitive despite becoming obese on both 
chow and HFD, which we postulate is a function of GPS2-AKO mice having increased 
lipid storage capacity in AT and a reduction of peripheral tissue lipid deposition. Our 
work validates that GPS2 also plays an anti-inflammatory role in AT under dietary 
stressed conditions. Preliminary work from GPS2-AKO mice exposed to HFD 
demonstrates they have increased AT inflammation and macrophage infiltration, however 
this does not influence the metabolic flexibility of these mice. Thus, this work suggests 
that enhanced insulin signaling outmaneuvers effects of increased inflammatory signaling 
events in adipocytes, pointing to a shift in the paradigm of thinking for treating T2D and 
metabolic diseases.  
		
138 
Future directions: The role of GPS2 in regulating AKT in the insulin signaling 
cascade 
 In this work, we have identified a novel mechanism of regulation in the insulin 
signaling cascade in which AKT undergoes GPS2 and Ubc13 regulated K63 
ubiquitination for proper phosphorylation and activation86. An unanswered question of 
this work is mechanistically why K63 ubiquitination is necessary for AKT full activation 
in insulin signaling. We hypothesize that it helps drive AKT to the plasma membrane, as 
previously suggested in the case of IGF and EGF-mediated AKT activation40,41. In order 
to address this question, it would be useful to perform fractionation experiments to see if 
modulation of GPS2 and Ubc13 could affect AKT membrane translocation upon insulin 
stimulation. Recent evidence has suggested that p62, a known K63 ubiquitin binding 
protein, helps bridge interactions between IRS-1 and AKT at the membrane upon insulin 
stimulation227. This finding could help explain why this specific posttranslational 
modification of AKT is important for the activation of the insulin signaling cascade by 
allowing interactions with key components at the plasma membrane. Future experiments 
modulating p62 could help answer these pressing questions and further dissect the 
mechanism of AKT activation.  
Prior to the studies reported in this thesis, AKT K63 ubiquitination has been 
studied in the context of cancer models36-39. Mutations that add an additional lysine 
residue in the PH domain of AKT exhibit hyperactive AKT signaling in this context43. 
These data suggest that K63 ubiquitination is an important posttranslational modification 
that can govern AKT signaling in cancer. Therefore, it would be interesting to see if 
		
139 
defects in GPS2-mediated regulation of AKT activation are involved in tumors, 
especially with dysfunctional AKT/PI3K signaling. Evidence of this has been suggested 
in work showing that GPS2 acts as a tumor suppressor in liposarcomas228. Therefore, 
studying the role of GPS2 in cancer progression could prove to be useful and 
advantageous in the search for novel targets for cancer treatment.  
Lastly, K63 ubiquitination has emerged as an increasingly common 
posttranslational modification in signal transduction pathways229. It would be useful to 
expand the studies of GPS2 and Ubc13 regulation to see if their modulation of kinase 
activation is conserved with different growth factor stimulation and extends to additional 
signaling pathways involved in metabolic homeostasis. This method of regulation could 
help further explain how metabolic pathways are coordinated within a cell.  
Future directions: GPS2 regulation of adipose tissue lipid storage capacity, 
mitochondrial biogenesis and whole body metabolism 
 In this thesis, we have shown how GPS2 regulates various pathways involved in 
metabolic regulation of an adipocyte. Lipolysis, lipogenesis, and mitochondrial function 
are tightly linked in the coordinated response of a cell to fasting and feeding121,122,230. 
Data showing that GPS2 can regulate all these processes leads us to speculate that it may 
be involved in managing communication within a cell to regulate metabolic responses 
from the level of signal transduction to transcriptional input as a metabolic integrator. In 
this context, it will be worth exploring the mechanism by which GPS2 can directly 
regulate lipogenic gene expression, and whether this could be a function of GPS2 with 
the NCoR/SMRT corepressor complex, as our data suggests GPS2 binding on lipogenic 
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gene promoters. In addition, our work indicates that GPS2 is localized in the cytoplasm, 
nucleus and mitochondria. In future directions, it would be extremely interesting to 
understand if GPS2 compartmentalization could lead to coordinated activation and 
inactivation of energy storage, utilization and oxidative phosphorylation during fasting 
and feeding cycles. More extensive studies in understanding GPS2 localization during 
fasting or growth factor stimulation can help answer some of these questions. We 
envision a network whereby, in fasting conditions, endogenous GPS2 is present in the 
cytoplasm to inhibit AKT activation and mitochondrial GPS2 translocates into the 
nucleus to positively and negatively regulate gene expression of mitochondrial and 
lipogenic genes, respectively. Under feeding conditions, we speculate that GPS2 is 
sequestered out of the cytoplasm, to allow for AKT activation, possibly by retaining it in 
the mitochondria whereby it is not permissive to enter the nucleus. Much greater detailed 
exploration of these mechanisms is required to prove these hypotheses but they open the 
possibility that GPS2 plays a key role in the coordinated regulation of metabolic 
homeostasis.  
On a systems level, we have shown that enhancing mechanisms involved in 
positively regulating AT lipid storage concurs with improvements in systemic 
metabolism. These data suggest that these pathways could be the most successful targets 
to efficaciously treat metabolic diseases. Interestingly, a study parallel to ours showed 
that GPS2-AKO mice were not protected from insulin resistance under 60% HFD108 
whereas our work revealed that GPS2-AKO mice fed either chow or 45% HFD diet 
remain insulin sensitive, despite being obese86. The discrepancies in these data could 
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suggest that there are inherent differences as to how these models were generated or, 
more interestingly, that there is a threshold for the level of protection from insulin 
resistance with a loss of GPS2. Further characterization of the metabolic health of GPS2-
AKO mice during the progression of either 45% or 60% HFD would be useful to 
undertake. Using comparisons between these diet treatments could help answer the 
question of whether there is indeed a threshold of GPS2 protection and, if so, whether it 
is uncontrolled lipid spillover on 60% HFD that causes insulin resistance rather than 
increased AT inflammation, which is observed under both diet regimens. 
Future directions: GPS2 effects on inflammation and macrophage infiltration 
Our current work in characterizing GPS2-AKO mice on HFD shows that these 
mice are protected from systemic metabolic dysfunction despite severe obesity and 
increased AT inflammation, however more work in characterizing the local and systemic 
inflammation in this mouse model is required. This work supports various data 
suggesting AT inflammation is not the sole insulin resistance driver and treating T2D 
with anti-inflammatory drugs may not be the most appropriate choice. For the future 
directions in understanding how GPS2 regulates inflammation, we plan to continue the 
characterization of the inflammatory profile of GPS2-AKO mice on HFD. Evidence 
suggests that these mice have increased macrophage infiltration however we are currently 
unclear about the function of these macrophages. It would be useful to answer the 
question of whether these macrophages display polarization of a specific M1 vs M2 
phenotype to clarify why increased AT inflammation is not driving insulin resistance in 
this model under dietary stress. We hypothesize that these macrophages might be helping 
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to remodel AT to allow for enhanced expansion. We propose this is in part based on 
reports showing macrophages help to recruit progenitors223. To verify these hypotheses, 
future directions will also include experiments to sort and profile macrophages and 
progenitor cells within AT depots of GPS2-AKO mice.  
Furthermore, data showing that GPS2 and Ubc13 regulate both the insulin 
signaling pathway and TNFa/TLR pro-inflammatory signaling cascades, suggest that 
there is significantly more integration between these pathways than previously described 
especially in regards to how these pathways can influence each other upon metabolic 
disease progression84-86. Interestingly, in cells lacking TRAF6, TNFa stimulation led to 
prolonged hyperphosphorylation of AKT, which coincided with the activation of 
upstream PI3K, suggesting these pathways are tightly intertwined231. These studies again 
point to GPS2 as a mediator of Futures studies in understanding the interplay between 
these pathways and how/when they are both regulated by GPS2 and Ubc13 will provide 
insight into how impaired adipocyte insulin signaling and increased AT inflammation 
instigate each other in the development of insulin resistance.  
Concluding remarks  
In conclusion, this project highlights the importance of gaining a better 
understanding of the casual relationship between lipid storage and obesity, inflammation, 
and insulin resistance. The studies performed in this thesis display extensive evidence 
that GPS2 acts as a key metabolic integrator within AT with great implications in 
systemic coordination of metabolism as well. Our recent studies, along with the previous 
studies of GPS2 in liver and immune cells, from seemingly diverse research areas, all 
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suggest that regulation of lipid metabolism and inflammation through GPS2 is 
fundamental to many physiologic and pathophysiologic metabolic processes. GPS2 
appears to act to coordinately modulate metabolic pathways within a cell to regulate 
responses to nutritional cues in a synchronized manner. The coordinated actions of GPS2 
allow full integration of signal transduction cascades between various cellular 
compartments and organelles, ultimately transmitting these signals into transcriptional 
program regulation. Furthermore, these studies uncover the important role of non-
proteolytic ubiquitination as a novel, unappreciated regulatory mechanism in AT and 
immune cell metabolic pathways. This thesis represents an innovative means to 
comprehensively investigate the complex relationship between lipid flux and 
inflammation in the development of insulin resistance with important implications for the 
design of effective therapeutic approaches against T2D. This project is significant 
because understanding the role of GPS2 in AT has the potential of providing insightful 
information for the development of new treatments against obesity-associated metabolic 
disorders.   
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